Johnson & Johnson (JNJ) 10-Q 29 Jul 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jul. 03, 2022	Jul. 22, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 03, 2022
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	Johnson & Johnson
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,629,179,895
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--01-01
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Stock, Par Value $1.00
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Entity Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ24C
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Entity Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ24BP
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Entity Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ28
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Entity Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ35
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jul. 03, 2022	Jan. 02, 2022
Current assets:
Cash and cash equivalents	$ 10,983	$ 14,487
Marketable securities	21,585	17,121
Accounts receivable, trade, less allowances $223 (2021, $230)	16,139	15,283
Inventories (Note 2)	11,437	10,387
Prepaid expenses and other	3,703	3,701
Total current assets	63,847	60,979
Property, plant and equipment at cost	47,144	47,679
Less: accumulated depreciation	(28,790)	(28,717)
Property, plant and equipment, net	18,354	18,962
Intangible assets, net (Note 3)	42,408	46,392
Goodwill (Note 3)	34,166	35,246
Deferred taxes on income (Note 5)	9,514	10,223
Other assets	9,435	10,216
Total assets	177,724	182,018
Current liabilities:
Loans and notes payable	4,305	3,766
Accounts payable	9,765	11,055
Accrued liabilities	12,607	13,612
Accrued rebates, returns and promotions	13,447	12,095
Accrued compensation and employee related obligations	2,717	3,586
Accrued taxes on income (Note 5)	1,980	1,112
Total current liabilities	44,821	45,226
Long-term debt (Note 4)	28,292	29,985
Deferred taxes on income (Note 5)	5,015	7,487
Employee related obligations (Note 6)	8,553	8,898
Long-term taxes payable (Note 5)	4,162	5,713
Other liabilities	10,524	10,686
Total liabilities	101,367	107,995
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(13,843)	(13,058)
Retained earnings	126,216	123,060
Less: common stock held in treasury, at cost (490,811,000 and 490,878,000 shares)	39,136	39,099
Total shareholders’ equity	76,357	74,023
Total liabilities and shareholders' equity	$ 177,724	$ 182,018

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jul. 03, 2022	Jan. 02, 2022
Current assets:
Allowances for doubtful accounts	$ 223	$ 230
Shareholders' equity:
Common stock, par value per share (per share)	$ 1	$ 1
Common stock, shares authorized (in shares)	4,320,000,000	4,320,000,000
Common stock, shares issued (in shares)	3,119,843,000	3,119,843,000
Treasury stock, shares (in shares)	490,811,000	490,878,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Income Statement [Abstract]
Sales to customers	$ 24,020	$ 23,312	$ 47,446	$ 45,633
Sales to customers percent to sales	100%	100%	100%	100%
Cost of products sold	$ 7,919	$ 7,587	$ 15,517	$ 14,650
Cost of products sold percent to sales	33%	32.50%	32.70%	32.10%
Gross profit	$ 16,101	$ 15,725	$ 31,929	$ 30,983
Gross Profit Percent To Sales	67%	67.50%	67.30%	67.90%
Selling, marketing and administrative expenses	$ 6,226	$ 6,073	$ 12,164	$ 11,505
Selling marketing and administrative expenses percent to sales	25.90%	26.10%	25.60%	25.20%
Research and development expense	$ 3,703	$ 3,394	$ 7,165	$ 6,572
Research and development expense percent to sales	15.40%	14.60%	15.10%	14.40%
In-process research and development			$ 610	$ 0
In-process research and development percent to sales			1.30%	0%
Interest income	$ (64)	$ (12)	$ (86)	$ (27)
Interest income percent to sales	(0.30%)	(0.10%)	(0.20%)	0%
Interest expense, net of portion capitalized	$ 38	$ 40	$ 48	$ 103
Interest expense, net of portion capitalized percent to sales	0.20%	0.20%	0.10%	0.20%
Other (income) expense, net	$ 273	$ (488)	$ 171	$ (1,370)
Other (income) expense, net percent to sales	1.10%	(2.10%)	0.40%	(3.00%)
Restructuring (Note 12)	$ 85	$ 56	$ 155	$ 109
Restructuring charge percent to sales	0.40%	0.20%	0.30%	0.20%
Earnings before provision for taxes on income	$ 5,840	$ 6,662	$ 11,702	$ 14,091
Earnings before provision for taxes on income percent to sales	24.30%	28.60%	24.70%	30.90%
Provision for taxes on income (Note 5)	$ 1,026	$ 384	$ 1,739	$ 1,616
Provision for taxes on income percent to sales	4.30%	1.70%	3.70%	3.60%
Net earnings	$ 4,814	$ 6,278	$ 9,963	$ 12,475
Net earnings percent to sales	20%	26.90%	21%	27.30%
NET EARNINGS PER SHARE
Basic (per share)	$ 1.83	$ 2.38	$ 3.79	$ 4.74
Diluted (per share)	$ 1.80	$ 2.35	$ 3.73	$ 4.67
AVG. SHARES OUTSTANDING
Basic (shares)	2,629.6	2,632.5	2,629.4	2,632
Diluted (shares)	2,667.9	2,671.6	2,669.2	2,674

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Statement of Comprehensive Income [Abstract]
Net earnings	$ 4,814	$ 6,278	$ 9,963	$ 12,475
Other comprehensive income (loss), net of tax
Foreign currency translation	(151)	(135)	(705)	141
Securities:
Unrealized holding gain (loss) arising during period	(20)	(1)	(33)	(1)
Reclassifications to earnings	0	0	0	0
Net change	(20)	(1)	(33)	(1)
Employee benefit plans:
Prior service cost amortization during period	(20)	(41)	(73)	(82)
Gain (loss) amortization during period	86	275	303	549
Net change	66	234	230	467
Derivatives & hedges:
Unrealized gain (loss) arising during period	145	400	(50)	(122)
Reclassifications to earnings	(126)	(270)	(227)	(343)
Net change	19	130	(277)	(465)
Other comprehensive income (loss)	(86)	228	(785)	142
Comprehensive income	$ 4,728	$ 6,506	$ 9,178	$ 12,617

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Statement of Comprehensive Income [Abstract]
Foreign Currency Translation	$ 533	$ (90)	$ 678	$ 229
Securities	(6)		(9)
Employee Benefit Plans	(84)	(66)	(65)	(132)
Derivatives & Hedges	$ 5	$ 33	$ (73)	$ (124)

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Retained Earnings	Accumulated Other Comprehensive Income	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Jan. 03, 2021	$ 63,278	$ 113,890	$ (15,242)	$ 3,120	$ (38,490)
Net earnings	12,475	12,475
Cash dividends paid	(5,450)	(5,450)
Employee compensation and stock option plans	1,204	(761)			1,965
Repurchase of common stock	(2,069)				(2,069)
Other comprehensive income (loss), net of tax	142		142
Ending Balance at Jul. 04, 2021	69,580	120,154	(15,100)	3,120	(38,594)
Beginning Balance at Apr. 04, 2021	65,834	116,508	(15,328)	3,120	(38,466)
Net earnings	6,278	6,278
Cash dividends paid	(2,791)	(2,791)
Employee compensation and stock option plans	662	159			503
Repurchase of common stock	(631)				(631)
Other comprehensive income (loss), net of tax	228		228
Ending Balance at Jul. 04, 2021	69,580	120,154	(15,100)	3,120	(38,594)
Beginning Balance at Jan. 02, 2022	74,023	123,060	(13,058)	3,120	(39,099)
Net earnings	9,963	9,963
Cash dividends paid	(5,758)	(5,758)
Employee compensation and stock option plans	1,464	(1,049)			2,513
Repurchase of common stock	(2,550)				(2,550)
Other comprehensive income (loss), net of tax	(785)		(785)
Ending Balance at Jul. 03, 2022	76,357	126,216	(13,843)	3,120	(39,136)
Beginning Balance at Apr. 03, 2022	74,709	124,380	(13,757)	3,120	(39,034)
Net earnings	4,814	4,814
Cash dividends paid	(2,971)	(2,971)
Employee compensation and stock option plans	864	(7)			871
Repurchase of common stock	(973)				(973)
Other comprehensive income (loss), net of tax	(86)		(86)
Ending Balance at Jul. 03, 2022	$ 76,357	$ 126,216	$ (13,843)	$ 3,120	$ (39,136)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 1.13	$ 1.06	$ 2.19	$ 2.07

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 9,963	$ 12,475
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	3,513	3,733
Stock based compensation	644	661
Asset write-downs	747	26
Net gain on sale of assets/businesses	(213)	(601)
Deferred tax provision	(2,349)	(685)
Credit losses and accounts receivable allowances	(3)	(52)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(1,386)	(1,566)
Increase in inventories	(1,257)	(818)
Decrease in accounts payable and accrued liabilities	(1,170)	(4,050)
Decrease in other current and non-current assets	3,527	1,415
Decrease in other current and non-current liabilities	(2,456)	(1,150)
NET CASH FLOWS FROM OPERATING ACTIVITIES	9,560	9,388
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(1,470)	(1,490)
Proceeds from the disposal of assets/businesses, net (Note 10)	314	654
Acquisitions, net of cash acquired (Note 10)	(523)	0
Purchases of investments	(22,048)	(12,264)
Sales of investments	17,634	12,453
Credit support agreements activity, net	(10)	441
Other (primarily licenses and milestones)	(170)	(398)
NET CASH USED BY INVESTING ACTIVITIES	(6,273)	(604)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(5,758)	(5,450)
Repurchase of common stock	(2,550)	(2,069)
Proceeds from short-term debt	4,371	498
Repayment of short-term debt	(2,201)	(689)
Proceeds from long-term debt, net of issuance costs	2	1
Repayment of long-term debt	(2,132)	(1,451)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	820	543
Credit support agreements activity, net	813	130
Other	(11)	83
NET CASH USED BY FINANCING ACTIVITIES	(6,646)	(8,404)
Effect of exchange rate changes on cash and cash equivalents	(145)	(33)
(Decrease)/Increase in cash and cash equivalents	(3,504)	347
Cash and Cash equivalents, beginning of period	14,487	13,985
CASH AND CASH EQUIVALENTS, END OF PERIOD	10,983	14,332
Acquisitions
Fair value of assets acquired	621	0
Fair value of liabilities assumed and noncontrolling interests	(98)	0
Net cash paid for acquisitions	$ 523	$ 0

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jul. 03, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. Use of Estimates The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of July 3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended July 3, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022. There were no new material accounting standards issued in the fiscal second quarter of 2022 that impacted the Company. Recently Adopted Accounting Standards There were no new material accounting standards adopted in the fiscal second quarter of 2022. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Inventories

Inventories	6 Months Ended
	Jul. 03, 2022
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) July 3, 2022 January 2, 2022 Raw materials and supplies $ 1,696 1,592 Goods in process 2,324 2,287 Finished goods 7,417 6,508 Total inventories $ 11,437 10,387

Intangible Assets and Goodwill

Intangible Assets and Goodwill	6 Months Ended
	Jul. 03, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) July 3, 2022 January 2, 2022 Intangible assets with definite lives: Patents and trademarks — gross $ 36,885 38,572 Less accumulated amortization (20,336) (20,088) Patents and trademarks — net 16,549 18,484 Customer relationships and other intangibles — gross 22,558 23,011 Less accumulated amortization (12,269) (11,925) Customer relationships and other intangibles — net (1) 10,289 11,086 Intangible assets with indefinite lives: Trademarks 6,794 6,985 Purchased in-process research and development (2) 8,776 9,837 Total intangible assets with indefinite lives 15,570 16,822 Total intangible assets — net $ 42,408 46,392 (1) The majority is comprised of customer relationships (2) In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives. Goodwill as of July 3, 2022 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical MedTech Total Goodwill at January 2, 2022 $ 9,810 10,580 14,856 35,246 Goodwill, related to acquisitions — — 195 195 Currency translation/Other (665) (545) (65) (1,275) Goodwill at July 3, 2022 $ 9,145 10,035 14,986 34,166 The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion and $1.2 billion for the fiscal second quarters ended July 3, 2022 and July 4, 2021, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $2.2 billion and $2.4 billion for the fiscal six months ended July 3, 2022 and July 4, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2022 2023 2024 2025 2026 $4,400 4,400 4,200 3,400 2,800 See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jul. 03, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of July 3, 2022, the cumulative amount of cash collateral received by the Company under the CSA amounted to $233.0 million net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of July 3, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $46.7 billion, $37.2 billion and $10.0 billion, respectively. As of January 2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion, $37.4 billion and $10.0 billion respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of July 3, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $613 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended in 2022 and 2021, net of tax: July 3, 2022 July 4, 2021 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (241) — — — — (6) — Derivatives designated as hedging instruments — — — 241 — — — — 6 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 44 — — — — 40 — Amount of gain or (loss) recognized in AOCI — — — 44 — — — — 40 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (17) (6) 42 — (39) 11 14 104 — 2 Amount of gain or (loss) recognized in AOCI (25) 35 69 — (38) (3) (50) 119 — 8 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 102 — — — 99 — Amount of gain or (loss) recognized in AOCI $ — — — 60 — — — — 286 — The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended in 2022 and 2021, net of tax: July 3, 2022 July 4, 2021 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (772) — — — — (6) — Derivatives designated as hedging instruments — — — 772 — — — — 6 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 89 — — — — 80 — Amount of gain or (loss) recognized in AOCI — — — 89 — — — — 80 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (34) (58) 65 — (57) 28 48 (9) — 5 Amount of gain or (loss) recognized in AOCI (3) (59) 102 — (111) (6) (243) 43 — 25 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 222 — — — — 191 — Amount of gain or (loss) recognized in AOCI $ — — — (68) — — — — (21) — As of July 3, 2022, and January 2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) July 3, 2022 January 2, 2022 July 3, 2022 January 2, 2022 Long-term Debt $ 9,035 9,793 (1,010) (142) The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended 2022 and 2021: Gain/(Loss) Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Second Quarter Ended Fiscal Six Months Ended Derivatives Not Designated as Hedging Instruments July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 Foreign Exchange Contracts Other (income) expense $ 73 (21) 102 (37) The following table is the effect of net investment hedges for the fiscal second quarters ended in 2022 and 2021: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 Debt $ 202 (45) Interest (income) expense — — Cross Currency interest rate swaps $ 313 (70) Interest (income) expense — — The following table is the effect of net investment hedges for the fiscal six months ended in 2022 and 2021 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 Debt $ 270 164 Interest (income) expense — — Cross Currency interest rate swaps $ 873 291 Interest (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments: (Dollars in Millions) January 2, 2022 July 3, 2022 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,884 (508) (36) 1,340 1,340 Equity Investments without readily determinable value $ 500 (14) 35 521 521 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For equity investments without readily determinable market values, there was a decrease of $14 million in the fair value reflected in net income as a result of impairments. Subsequent to the fiscal second quarter ended July 3, 2022, the Company sold all of its shares in argenx SE for proceeds of $0.6 billion. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of July 3, 2022 and January 2, 2022 were as follows: July 3, 2022 January 2, 2022 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 1,314 — 1,314 540 Interest rate contracts (2) — 1,979 — 1,979 796 Total — 3,293 — 3,293 1,336 Liabilities: Forward foreign exchange contracts — 1,513 — 1,513 881 Interest rate contracts (2) — 1,540 — 1,540 979 Total — 3,053 — 3,053 1,860 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 47 — 47 24 Liabilities: Forward foreign exchange contracts — 44 — 44 28 Other Investments: Equity investments (3) 1,340 — — 1,340 1,884 Debt securities (4) — 21,123 — 21,123 19,727 Other Liabilities Contingent consideration (5) $ — — 536 536 533 Gross to Net Derivative Reconciliation July 3, 2022 January 2, 2022 (Dollars in Millions) Total Gross Assets $ 3,340 1,360 Credit Support Agreement (CSA) (3,226) (1,285) Total Net Asset 114 75 Total Gross Liabilities 3,097 1,888 Credit Support Agreement (CSA) (2,993) (1,855) Total Net Liabilities $ 104 33 Summarized information about changes in liabilities for contingent consideration is as follows: July 3, 2022 July 4, 2021 (Dollars in Millions) Beginning Balance $ 533 $ 633 Changes in estimated fair value (6) (88) 8 Additions 91 — Payments — (48) Ending Balance $ 536 $ 593 (1) 2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified within cash equivalents and current marketable securities. (5) Includes $519 million and $520 million, classified as non-current other liabilities as of July 3, 2022 and January 2, 2022, respectively. Includes $17 million and $13 million classified as current liabilities as of July 3, 2022 and January 2, 2022, respectively. (6) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. The Company's cash, cash equivalents and current marketable securities as of July 3, 2022 comprised: (Dollars in Millions) Carrying Amount Gain/( Loss) Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,337 — 3,337 3,337 — Non-U.S. sovereign securities (1) 538 (1) 537 — 538 U.S. reverse repurchase agreements 2,112 — 2,112 2,112 — Corporate debt securities (1) 2,443 (8) 2,435 240 2,203 Money market funds 1,968 — 1,968 1,968 — Time deposits (1) 1,047 — 1,047 1,047 — Subtotal 11,445 (9) 11,436 8,704 2,741 Unrealized Loss U.S. Gov't securities 20,919 (45) 20,874 2,251 18,623 Other sovereign securities 3 — 3 — 3 Corporate debt securities 247 (1) 246 28 218 Subtotal available for sale debt (2) $ 21,169 (46) 21,123 2,279 18,844 Total cash, cash equivalents and current marketable securities $ 32,614 (55) 32,559 10,983 21,585 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. As of the fiscal year ended January 2, 2022 the carrying amount was approximately the same as the estimated fair value. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities. The contractual maturities of the available for sale securities as of July 3, 2022 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 21,155 21,109 Due after one year through five years 14 14 Due after five years through ten years — — Total debt securities $ 21,169 21,123 Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of July 3, 2022: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 4,305 4,304 Non-Current Debt 6.73% Debentures due 2023 250 263 3.375% Notes due 2023 802 805 0.650% Notes due 2024 (750MM Euro 1.0408) 774 766 5.50% Notes due 2024 (500MM GBP 1.2143) 605 647 2.625% Notes due 2025 749 745 0.550% Notes due 2025 940 872 2.45% Notes due 2026 1,995 1,950 2.95% Notes due 2027 911 899 0.95% Notes due 2027 1,423 1,264 2.90% Notes due 2028 1,496 1,462 1.150% Notes due 2028 (750MM Euro 1.0408) 776 735 6.95% Notes due 2029 298 372 1.30% Notes due 2030 1,646 1,404 4.95% Debentures due 2033 498 554 4.375% Notes due 2033 855 895 1.650% Notes due 2035 (1.5B Euro 1.0408) 1,554 1,370 3.55% Notes due 2036 885 848 5.95% Notes due 2037 993 1,181 3.625% Notes due 2037 1,381 1,328 3.40% Notes due 2038 992 898 5.85% Debentures due 2038 697 817 4.50% Debentures due 2040 540 546 2.10% Notes due 2040 876 647 4.85% Notes due 2041 297 312 4.50% Notes due 2043 496 506 3.70% Notes due 2046 1,975 1,830 3.75% Notes due 2047 863 806 3.50% Notes due 2048 743 677 2.25% Notes due 2050 864 599 2.45% Notes due 2060 1,108 773 Other 10 10 Total Non-Current Debt $ 28,292 26,781 The weighted average effective interest rate on non-current debt is 3.04%. The excess of the estimated fair value over the carrying value of debt was $3.2 billion at January 2, 2022. The current debt balance as of July 3, 2022 includes $3.8 billion of commercial paper which has a weighted average interest rate of 0.98% and a weighted average maturity of approximately two months.

Income Taxes

Income Taxes	6 Months Ended
	Jul. 03, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the fiscal six months quarters of 2022 and 2021 were 14.9% and 11.5%, respectively. This increase in the consolidated tax rate as compared to the prior year fiscal quarter is primarily due to the Company reorganizing the ownership structure of certain wholly-owned international subsidiaries in the second fiscal quarter of 2021. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with the applicable local regulations. Accordingly the Company recorded a local deferred tax benefit of approximately $2.3 billion which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $1.7 billion. The net impact of this reorganization was approximately $0.6 billion net benefit or a 4.4% decrease to the effective tax rate of the fiscal six months of 2021. Additionally, the Company had lower income in higher tax jurisdictions, primarily in the U.S., compared to the same period in the prior year and certain one-time tax costs. This lower income in the fiscal six months of 2022 was primarily caused by a mark to market adjustment to the Company’s investment portfolio, the impairment of the Bermekimab AD IPR&D (for further information see Note 3 to the Consolidated Financial Statements), both at the U.S. statutory rate, and litigation expenses. The impact of the income mix was partially offset by incremental tax costs directly related to the planned separation of the Company’s Consumer Health business (for further information see Note 1 to the Consolidated Financial Statements) . The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during each of the fiscal second quarters. Additionally, the Company’s tax rate benefited from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022. As of July 3, 2022, the Company had approximately $3.4 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	6 Months Ended
	Jul. 03, 2022
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	PENSIONS AND OTHER BENEFIT PLANS Components of Net Periodic Benefit Cost Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components: Fiscal Second Quarter Ended Fiscal Six Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 Service cost $ 319 327 80 77 640 680 160 154 Interest cost 229 193 27 21 459 386 53 41 Expected return on plan assets (693) (647) (2) (2) (1,392) (1,327) (4) (4) Amortization of prior service cost/(credit) (46) (45) (2) (7) (92) (90) (3) (15) Recognized actuarial losses 167 316 31 37 329 630 61 75 Curtailments and settlements — — — — 1 1 — — Net periodic benefit cost/(credit) $ (24) 144 134 126 (55) 280 267 251 The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Company Contributions For the fiscal six months ended July 3, 2022, the Company contributed $54 million and $10 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Jul. 03, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 2, 2022 $ (10,017) (3) (2,702) (336) (13,058) Net change (705) (33) 230 (277) (785) July 3, 2022 $ (10,722) (36) (2,472) (613) (13,843) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jul. 03, 2022
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share: Fiscal Second Quarter Ended Fiscal Six Months Ended (Shares in Millions) July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 Basic net earnings per share $ 1.83 2.38 3.79 4.74 Average shares outstanding — basic 2,629.6 2,632.5 2,629.4 2,632.0 Potential shares exercisable under stock option plans 143.7 141.9 141.8 126.0 Less: shares which could be repurchased under treasury stock method (105.4) (102.8) (102.0) (84.0) Average shares outstanding — diluted 2,667.9 2,671.6 2,669.2 2,674.0 Diluted net earnings per share $ 1.80 2.35 3.73 4.67 The diluted net earnings per share calculation for both the fiscal second quarter ended July 3, 2022 and July 4, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company’s stock.

Segments of Business and Geogra

Segments of Business and Geographic Areas	6 Months Ended
	Jul. 03, 2022
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) July 3, July 4, Percent July 3, July 4, Percent Change CONSUMER HEALTH (1) OTC U.S. $ 663 675 (1.8) % $ 1,333 1,274 4.6 % International 818 752 8.8 1,609 1,425 12.9 Worldwide 1,482 1,426 3.8 2,943 2,699 9.0 Skin Health/Beauty U.S. 629 659 (4.5) 1,173 1,293 (9.2) International 497 511 (2.8) 965 1,040 (7.2) Worldwide 1,126 1,170 (3.7) 2,138 2,333 (8.3) Oral Care U.S. 170 165 3.4 313 328 (4.6) International 224 260 (14.1) 447 514 (13.0) Worldwide 394 426 (7.3) 760 843 (9.7) Baby Care U.S. 88 97 (9.1) 173 193 (10.3) International 287 290 (1.0) 557 583 (4.4) Worldwide 375 387 (3.1) 730 776 (5.9) Women's Health U.S. 3 3 8.9 7 6 8.1 International 228 227 0.1 452 446 1.3 Worldwide 230 230 0.2 458 452 1.4 Wound Care/Other U.S. 133 153 (12.7) 245 268 (8.6) International 65 64 1.7 117 125 (6.6) Worldwide 197 216 (8.4) 361 393 (8.0) TOTAL CONSUMER HEALTH U.S. 1,687 1,751 (3.6) 3,244 3,362 (3.5) International 2,118 2,103 0.6 4,147 4,133 0.3 Worldwide 3,805 3,854 (1.3) 7,391 7,495 (1.4) PHARMACEUTICAL (1) Immunology U.S. 2,853 2,748 3.8 5,354 5,161 3.7 International 1,559 1,483 5.1 3,176 2,984 6.4 Worldwide 4,411 4,231 4.3 8,530 8,145 4.7 REMICADE U.S. 391 540 (27.4) 749 1,029 (27.1) U.S. Exports 44 93 (53.0) 124 150 (17.5) International 212 255 (17.2) 437 487 (10.3) Worldwide 647 888 (27.2) 1,310 1,665 (21.4) SIMPONI / SIMPONI ARIA U.S. 301 290 3.8 588 545 7.9 International 266 294 (9.7) 549 601 (8.6) Worldwide 566 584 (3.0) 1,137 1,146 (0.8) STELARA U.S. 1,731 1,496 15.7 3,110 2,827 10.0 International 868 778 11.6 1,777 1,595 11.4 Worldwide 2,599 2,274 14.3 4,887 4,422 10.5 TREMFYA U.S. 382 325 17.7 773 599 29.1 International 214 155 38.3 413 298 38.6 Worldwide 597 479 24.4 1,187 897 32.3 OTHER IMMUNOLOGY U.S. 3 5 (50.1) 9 12 (24.8) International 0 1 * 0 3 * Worldwide 3 7 (59.2) 9 15 (39.0) Infectious Diseases U.S. 415 444 (6.4) 876 956 (8.3) International 901 575 56.8 1,737 1,060 63.9 Worldwide 1,316 1,018 29.3 2,613 2,016 29.6 COVID-19 VACCINE U.S. 45 51 (11.5) 120 151 (20.4) International 499 113 * 881 113 * Worldwide 544 164 * 1,001 264 * EDURANT / rilpivirine U.S. 9 9 (1.7) 18 19 (7.4) International 215 253 (14.7) 454 486 (6.5) Worldwide 225 262 (14.3) 473 505 (6.5) PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 355 368 (3.4) 724 748 (3.2) International 110 137 (20.2) 242 303 (20.3) Worldwide 464 505 (7.9) 965 1,051 (8.1) OTHER INFECTIOUS DISEASES U.S. 6 16 (62.5) 14 37 (62.5) International 77 71 7.4 160 158 1.3 Worldwide 83 88 (5.4) 174 196 (10.9) Neuroscience U.S. 896 842 6.5 1,739 1,613 7.9 International 837 963 (13.0) 1,735 1,906 (8.9) Worldwide 1,734 1,804 (3.9) 3,475 3,519 (1.2) CONCERTA / methylphenidate U.S. 38 35 9.4 73 82 (11.3) International 123 127 (2.2) 245 250 (1.7) Worldwide 161 161 0.3 318 332 (4.1) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 691 645 7.3 1,352 1,234 9.6 International 362 380 (4.6) 749 756 (0.8) Worldwide 1,054 1,024 2.9 2,102 1,989 5.7 RISPERDAL CONSTA U.S. 65 72 (8.9) 128 139 (7.7) International 60 84 (28.0) 126 173 (27.1) Worldwide 125 155 (19.3) 254 312 (18.4) OTHER NEUROSCIENCE U.S. 102 91 11.8 186 158 17.6 International 292 373 (21.8) 615 728 (15.5) Worldwide 393 464 (15.2) 800 886 (9.6) Oncology U.S. 1,679 1,462 14.9 3,261 2,839 14.9 International 2,362 2,073 14.0 4,731 4,266 10.9 Worldwide 4,042 3,535 14.3 7,992 7,105 12.5 DARZALEX U.S. 1,021 770 32.6 1,974 1,461 35.1 International 965 663 45.5 1,868 1,337 39.7 Worldwide 1,986 1,433 38.6 3,842 2,798 37.3 ERLEADA U.S. 233 193 20.6 439 364 20.4 International 218 109 * 412 199 * Worldwide 450 302 49.5 850 563 51.1 IMBRUVICA U.S. 349 454 (23.1) 719 898 (19.9) International 620 662 (6.3) 1,288 1,342 (4.0) Worldwide 970 1,116 (13.1) 2,008 2,241 (10.4) ZYTIGA / abiraterone acetate U.S. 19 21 (12.2) 38 71 (47.0) International 486 542 (10.2) 1,006 1,130 (11.0) Worldwide 505 563 (10.3) 1,044 1,201 (13.1) OTHER ONCOLOGY U.S. 57 23 * 91 44 * International 72 97 (25.7) 156 258 (39.4) Worldwide 130 120 7.5 248 302 (18.0) Pulmonary Hypertension U.S. 560 595 (5.8) 1,132 1,168 (3.1) International 284 275 2.8 563 563 (0.1) Worldwide 843 870 (3.1) 1,695 1,731 (2.1) OPSUMIT U.S. 265 290 (8.7) 538 562 (4.3) International 173 172 0.5 343 351 (2.2) Worldwide 438 463 (5.3) 881 913 (3.5) UPTRAVI U.S. 272 268 1.4 541 527 2.6 International 56 45 26.2 112 91 23.5 Worldwide 328 313 4.9 653 618 5.7 OTHER PULMONARY HYPERTENSION U.S. 23 36 (36.2) 53 78 (32.3) International 55 59 (8.1) 108 122 (11.7) Worldwide 78 95 (18.7) 161 200 (19.8) Cardiovascular / Metabolism / Other U.S. 757 780 (3.0) 1,429 1,579 (9.5) International 215 241 (10.9) 453 486 (6.9) Worldwide 972 1,021 (4.8) 1,882 2,065 (8.9) XARELTO U.S. 609 569 7.1 1,117 1,158 (3.5) International — — — — — — Worldwide 609 569 7.1 1,117 1,158 (3.5) INVOKANA / INVOKAMET U.S. 55 96 (42.9) 115 183 (37.1) International 65 64 2.4 133 127 4.9 Worldwide 120 160 (24.9) 248 310 (19.9) OTHER (2) U.S. 93 116 (19.5) 197 238 (17.2) International 150 178 (15.6) 320 360 (11.1) Worldwide 243 293 (17.2) 517 598 (13.5) TOTAL PHARMACEUTICAL U.S. 7,159 6,869 4.2 13,791 13,315 3.6 International 6,158 5,611 9.8 12,395 11,266 10.0 Worldwide 13,317 12,480 6.7 26,186 24,581 6.5 MEDTECH (3) Interventional Solutions U.S. 525 475 10.5 1,019 909 12.1 International 525 572 (8.1) 1,123 1,086 3.4 Worldwide 1,049 1,046 0.3 2,141 1,995 7.4 Orthopaedics U.S. 1,338 1,323 1.1 2,627 2,572 2.1 International 820 904 (9.3) 1,719 1,768 (2.8) Worldwide 2,157 2,227 (3.1) 4,345 4,340 0.1 HIPS U.S. 240 233 3.4 465 442 5.2 International 148 159 (6.6) 312 305 2.4 Worldwide 388 391 (0.7) 777 747 4.1 KNEES U.S. 216 210 2.9 417 395 5.6 International 133 140 (4.6) 271 272 (0.4) Worldwide 349 350 (0.1) 688 667 3.1 TRAUMA U.S. 464 447 3.9 939 897 4.7 International 232 263 (11.8) 505 545 (7.4) Worldwide 696 710 (1.9) 1,444 1,443 0.1 SPINE, SPORTS & OTHER U.S. 418 434 (3.7) 805 838 (3.9) International 306 343 (10.6) 630 646 (2.4) Worldwide 724 777 (6.8) 1,436 1,484 (3.2) Surgery U.S. 992 1,035 (4.1) 1,913 1,933 (1.0) International 1,458 1,487 (2.0) 2,971 2,961 0.3 Worldwide 2,450 2,522 (2.8) 4,884 4,894 (0.2) ADVANCED U.S. 454 459 (1.1) 871 864 0.8 International 702 708 (0.9) 1,431 1,421 0.7 Worldwide 1,156 1,168 (1.0) 2,302 2,286 0.7 GENERAL U.S. 538 576 (6.4) 1,042 1,069 (2.5) International 756 779 (3.0) 1,540 1,540 0.0 Worldwide 1,294 1,354 (4.5) 2,582 2,608 (1.0) Vision U.S. 496 467 6.2 1,017 939 8.3 International 745 716 4.0 1,481 1,389 6.6 Worldwide 1,241 1,183 4.9 2,498 2,328 7.3 CONTACT LENSES / OTHER U.S. 374 352 6.6 774 723 7.2 International 519 517 0.4 1,030 1,003 2.7 Worldwide 894 868 2.9 1,804 1,725 4.5 SURGICAL U.S. 122 115 5.1 243 216 12.1 International 225 199 13.6 451 386 17.0 Worldwide 347 314 10.5 694 602 15.2 TOTAL MEDTECH U.S. 3,351 3,299 1.6 6,576 6,353 3.5 International 3,547 3,679 (3.6) 7,293 7,204 1.2 Worldwide 6,898 6,978 (1.1) 13,869 13,557 2.3 WORLDWIDE U.S. 12,197 11,919 2.3 23,611 23,030 2.5 International 11,823 11,393 3.8 23,835 22,603 5.5 Worldwide $ 24,020 23,312 3.0 % $ 47,446 45,633 4.0 % *Percentage greater than 100% or not meaningful (1) Approximately $0.1 billion in the fiscal second quarter of 2021 and $0.2 billion in the fiscal six months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (2) Inclusive of PROCRIT / EPREX which was previously disclosed separately (3) Previously referred to as Medical Devices EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT* Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) July 3, July 4, Percent July 3, July 4, Percent Consumer Health (1) $ 784 866 (9.5) % $ 1,470 1,708 (13.9) % Pharmaceutical (2) 4,420 4,294 2.9 8,344 9,463 (11.8) MedTech (3) 1,141 1,746 (34.7) 2,618 3,375 (22.4) Segment earnings before provision for taxes 6,345 6,906 (8.1) 12,432 14,546 (14.5) Less: Expense not allocated to segments (4) 237 244 360 455 Less: Consumer Health separation costs 268 — 370 — Worldwide income before tax $ 5,840 6,662 (12.3) % $ 11,702 14,091 (17.0) % *The 2021 fiscal second quarter and six months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (1) Consumer Health includes: • Intangible amortization expense of $0.1 billion in both the fiscal second quarter of 2022 and 2021 and $0.2 billion in both the fiscal six months of 2022 and 2021. • Litigation expense of $0.1 billion in both the fiscal second quarters and fiscal six months of 2022 and 2021, primarily for talc related costs. (2) Pharmaceutical includes: • Divestiture gains of $0.6 billion in the fiscal six months of 2021 related to two brands outside the U.S. • Intangible amortization expense of $0.7 billion and $0.8 billion in the fiscal second quarter of 2022 and 2021, respectively. Intangible amortization expense of $1.5 billion and $1.7 billion in the fiscal six months of 2022 and 2021, respectively. • In the fiscal six months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. • A loss of $0.1 billion and a gain of $0.2 billion related to the change in the fair value of securities in the fiscal second quarter of 2022 and 2021, respectively. A loss of $0.5 billion and a gain of $0.1 billion related to the change in the fair value of securities in the fiscal six months of 2022 and 2021, respectively. • COVID-19 Vaccine supply network related costs of $0.2 billion in both the fiscal second quarter and fiscal six months 2022 In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal second quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9 billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. (3) MedTech includes: • Litigation expense of $0.3 billion in both the fiscal second quarters and fiscal six months of 2022 primarily pelvic mesh related costs. • A restructuring related charge of $0.2 billion and $0.1 billion in the fiscal six months of 2022 and 2021, respectively. • Intangible amortization expense of $0.3 billion in both the fiscal second quarter of 2022 and 2021 and $0.5 billion in both the fiscal six months of 2022 and 2021. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) July 3, 2022 July 4, 2021 Percent July 3, 2022 July 4, 2021 Percent Change United States $ 12,197 11,919 2.3 % $ 23,611 23,030 2.5 % Europe 6,085 5,668 7.3 12,109 11,082 9.3 Western Hemisphere, excluding U.S. 1,536 1,367 12.4 3,018 2,791 8.1 Asia-Pacific, Africa 4,202 4,358 (3.6) 8,708 8,730 (0.2) Total $ 24,020 23,312 3.0 % $ 47,446 45,633 4.0 %

Acquisitions and Divestitures

Acquisitions and Divestitures	6 Months Ended
	Jul. 03, 2022
Business Combinations [Abstract]
Acquisitions and Divestitures	ACQUISITIONS AND DIVESTITURESThere were no material acquisitions or divestitures in the fiscal first quarter and fiscal second quarter of 2022. During the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6 billion.

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jul. 03, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of July 3, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; XARELTO; body powders containing talc, primarily JOHNSON’S Baby Powder; INVOKANA; and ETHICON PHYSIOMESH Flexible Composite Mesh. As of July 3, 2022, in the United States there were approximately 190 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; 1,900 with respect to the PINNACLE Acetabular Cup System; 9,500 with respect to pelvic meshes; 2,100 with respect to RISPERDAL; 3,000 with respect to XARELTO; 40,300 with respect to body powders containing talc; 10 with respect to INVOKANA; 4,700 with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; and 1,300 with respect to ELMIRON. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation also has been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon’s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company’s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon’s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. While this brings an end to the appellate process, there will now be an individual case assessment process for the remaining group member claims. In March 2022, the Court appointed a barrister to prepare a written report and recommendation on the form and mechanism of the individual case assessment process, due by August 2022, with a court hearing on those findings later that month. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon’s pelvic mesh products. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of July 2022, there are approximately 126 active cases subject to these orders which are being reviewed and evaluated. Claims have also been filed against Ethicon and Johnson & Johnson alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. Ethicon and Johnson & Johnson also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company’s accruals. Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson; and JPI’s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson & Johnson announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation. A significant number of personal injury claims alleging that talc causes cancer were made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor’s direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI’s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers’ compensation statute or act (the Talc-Related Liabilities). In October 2021, notwithstanding the Company’s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson & Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. Opening briefs were filed in June 2022 and briefing is to be completed by September 2022. Additionally, an industrial talc class action was filed against the Company and others in New Jersey state court in May 2022. The case was subsequently removed to federal court. In July 2022, Imerys, and LTL, filed a motion to stay the industrial talc class action. The court heard oral argument and a ruling is expected at any time. While the New Jersey Bankruptcy Court’s order effectively stays all of the Company’s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed. The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2 billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2 billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants’ Committee (TCC), and the Future Claimants’ Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent’s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys’s insurers (the Mediation Parties) have since agreed to engage in mediation, which remains ongoing. In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company’s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding. In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC) (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing “talc-related claims” against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023. In February 2021, several of the Company’s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action. In February 2018, a securities class action lawsuit was filed against Johnson & Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson & Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that purchasers of Johnson & Johnson’s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiffs’ motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff’s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record. In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action, and Plaintiff filed a notice of appeal regarding the Bankruptcy Court’s order. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson & Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption In re Johnson & Johnson Talc Stockholder Derivative Litigation . In July 2020, a report was delivered to the Company’s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th e In re Johnson & Johnson Talc Stockholder Derivative Litigation . The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel’s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson & Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson & Johnson’s motion to dismiss pending a decision on Plaintiff’s motion for discovery. In July 2022, the Court denied Plaintiff's discovery motion. In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson & Johnson Savings Plan against Johnson & Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson & Johnson stock as a Johnson & Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants’ motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants’ motion was complete. In February 2021, the Court granted Defendants’ motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September 2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument. A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California’s Consumer Legal Remedies Act (CLRA) relating to JOHNSON’S Baby Powder. In that lawsuit, the plaintiffs allege that Johnson & Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second ame

Restructuring

Restructuring	6 Months Ended
	Jul. 03, 2022
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal second quarter of 2022, the Company recorded a net pre-tax charge of $128 million, which is included on the following lines of the Consolidated Statement of Earnings, $85 million in restructuring, $17 million in cost of products sold and $26 million in other (income) expense, net. In the fiscal six months of 2022, the Company recorded a net pre-tax charge of $200 million, which is included on the following lines of the Consolidated Statement of Earnings, $155 million in restructuring, $33 million in cost of products sold and $12 million in other (income) expense, net. Total project costs of approximately $2.0 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.1 billion to $2.3 billion by the completion of the program in December 2022. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal second quarter of 2022: (Dollars in Millions) Severance Asset Write-offs/Sales Other (2) Total Reserve balance, January 2, 2022 $ 112 — 25 137 Current year activity: Charges — (11) 211 200 Cash settlements (23) 35 (3) (214) (202) Settled non cash — (24) — (24) Reserve balance, July 3, 2022 (1) $ 89 — 22 111 (1) Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Represents gain on sale of assets The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jul. 03, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of July 3, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended July 3, 2022, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.
New and Recently Adopted Accounting Standards	New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022. There were no new material accounting standards issued in the fiscal second quarter of 2022 that impacted the Company. Recently Adopted Accounting Standards There were no new material accounting standards adopted in the fiscal second quarter of 2022.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.
Cash and Cash Equivalents	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jul. 03, 2022
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) July 3, 2022 January 2, 2022 Raw materials and supplies $ 1,696 1,592 Goods in process 2,324 2,287 Finished goods 7,417 6,508 Total inventories $ 11,437 10,387

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jul. 03, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	(Dollars in Millions) July 3, 2022 January 2, 2022 Intangible assets with definite lives: Patents and trademarks — gross $ 36,885 38,572 Less accumulated amortization (20,336) (20,088) Patents and trademarks — net 16,549 18,484 Customer relationships and other intangibles — gross 22,558 23,011 Less accumulated amortization (12,269) (11,925) Customer relationships and other intangibles — net (1) 10,289 11,086 Intangible assets with indefinite lives: Trademarks 6,794 6,985 Purchased in-process research and development (2) 8,776 9,837 Total intangible assets with indefinite lives 15,570 16,822 Total intangible assets — net $ 42,408 46,392 (1) The majority is comprised of customer relationships (2) In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The Company acquired all rights to bermekimab from XBiotech, Inc.in the fiscal year 2020. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.
Goodwill	Goodwill as of July 3, 2022 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical MedTech Total Goodwill at January 2, 2022 $ 9,810 10,580 14,856 35,246 Goodwill, related to acquisitions — — 195 195 Currency translation/Other (665) (545) (65) (1,275) Goodwill at July 3, 2022 $ 9,145 10,035 14,986 34,166
Intangible Asset Amortization Expense	The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2022 2023 2024 2025 2026 $4,400 4,400 4,200 3,400 2,800

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jul. 03, 2022
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended in 2022 and 2021, net of tax: July 3, 2022 July 4, 2021 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (241) — — — — (6) — Derivatives designated as hedging instruments — — — 241 — — — — 6 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 44 — — — — 40 — Amount of gain or (loss) recognized in AOCI — — — 44 — — — — 40 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (17) (6) 42 — (39) 11 14 104 — 2 Amount of gain or (loss) recognized in AOCI (25) 35 69 — (38) (3) (50) 119 — 8 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 102 — — — 99 — Amount of gain or (loss) recognized in AOCI $ — — — 60 — — — — 286 — The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended in 2022 and 2021, net of tax: July 3, 2022 July 4, 2021 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (772) — — — — (6) — Derivatives designated as hedging instruments — — — 772 — — — — 6 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 89 — — — — 80 — Amount of gain or (loss) recognized in AOCI — — — 89 — — — — 80 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (34) (58) 65 — (57) 28 48 (9) — 5 Amount of gain or (loss) recognized in AOCI (3) (59) 102 — (111) (6) (243) 43 — 25 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 222 — — — — 191 — Amount of gain or (loss) recognized in AOCI $ — — — (68) — — — — (21) — The following table is the effect of net investment hedges for the fiscal second quarters ended in 2022 and 2021: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 Debt $ 202 (45) Interest (income) expense — — Cross Currency interest rate swaps $ 313 (70) Interest (income) expense — — The following table is the effect of net investment hedges for the fiscal six months ended in 2022 and 2021 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 Debt $ 270 164 Interest (income) expense — — Cross Currency interest rate swaps $ 873 291 Interest (income) expense — —
Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet	As of July 3, 2022, and January 2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) July 3, 2022 January 2, 2022 July 3, 2022 January 2, 2022 Long-term Debt $ 9,035 9,793 (1,010) (142)
Schedule of Effect of Derivatives not Designated as Hedging Instruments	The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended 2022 and 2021: Gain/(Loss) Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Second Quarter Ended Fiscal Six Months Ended Derivatives Not Designated as Hedging Instruments July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 Foreign Exchange Contracts Other (income) expense $ 73 (21) 102 (37)
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments: (Dollars in Millions) January 2, 2022 July 3, 2022 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,884 (508) (36) 1,340 1,340 Equity Investments without readily determinable value $ 500 (14) 35 521 521 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of July 3, 2022 and January 2, 2022 were as follows: July 3, 2022 January 2, 2022 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 1,314 — 1,314 540 Interest rate contracts (2) — 1,979 — 1,979 796 Total — 3,293 — 3,293 1,336 Liabilities: Forward foreign exchange contracts — 1,513 — 1,513 881 Interest rate contracts (2) — 1,540 — 1,540 979 Total — 3,053 — 3,053 1,860 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 47 — 47 24 Liabilities: Forward foreign exchange contracts — 44 — 44 28 Other Investments: Equity investments (3) 1,340 — — 1,340 1,884 Debt securities (4) — 21,123 — 21,123 19,727 Other Liabilities Contingent consideration (5) $ — — 536 536 533 Gross to Net Derivative Reconciliation July 3, 2022 January 2, 2022 (Dollars in Millions) Total Gross Assets $ 3,340 1,360 Credit Support Agreement (CSA) (3,226) (1,285) Total Net Asset 114 75 Total Gross Liabilities 3,097 1,888 Credit Support Agreement (CSA) (2,993) (1,855) Total Net Liabilities $ 104 33 Summarized information about changes in liabilities for contingent consideration is as follows: July 3, 2022 July 4, 2021 (Dollars in Millions) Beginning Balance $ 533 $ 633 Changes in estimated fair value (6) (88) 8 Additions 91 — Payments — (48) Ending Balance $ 536 $ 593 (1) 2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified within cash equivalents and current marketable securities. (5) Includes $519 million and $520 million, classified as non-current other liabilities as of July 3, 2022 and January 2, 2022, respectively. Includes $17 million and $13 million classified as current liabilities as of July 3, 2022 and January 2, 2022, respectively.
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of July 3, 2022 comprised: (Dollars in Millions) Carrying Amount Gain/( Loss) Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 3,337 — 3,337 3,337 — Non-U.S. sovereign securities (1) 538 (1) 537 — 538 U.S. reverse repurchase agreements 2,112 — 2,112 2,112 — Corporate debt securities (1) 2,443 (8) 2,435 240 2,203 Money market funds 1,968 — 1,968 1,968 — Time deposits (1) 1,047 — 1,047 1,047 — Subtotal 11,445 (9) 11,436 8,704 2,741 Unrealized Loss U.S. Gov't securities 20,919 (45) 20,874 2,251 18,623 Other sovereign securities 3 — 3 — 3 Corporate debt securities 247 (1) 246 28 218 Subtotal available for sale debt (2) $ 21,169 (46) 21,123 2,279 18,844 Total cash, cash equivalents and current marketable securities $ 32,614 (55) 32,559 10,983 21,585 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities	The contractual maturities of the available for sale securities as of July 3, 2022 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 21,155 21,109 Due after one year through five years 14 14 Due after five years through ten years — — Total debt securities $ 21,169 21,123
Financial Liabilities not Measured at Fair Value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of July 3, 2022: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 4,305 4,304 Non-Current Debt 6.73% Debentures due 2023 250 263 3.375% Notes due 2023 802 805 0.650% Notes due 2024 (750MM Euro 1.0408) 774 766 5.50% Notes due 2024 (500MM GBP 1.2143) 605 647 2.625% Notes due 2025 749 745 0.550% Notes due 2025 940 872 2.45% Notes due 2026 1,995 1,950 2.95% Notes due 2027 911 899 0.95% Notes due 2027 1,423 1,264 2.90% Notes due 2028 1,496 1,462 1.150% Notes due 2028 (750MM Euro 1.0408) 776 735 6.95% Notes due 2029 298 372 1.30% Notes due 2030 1,646 1,404 4.95% Debentures due 2033 498 554 4.375% Notes due 2033 855 895 1.650% Notes due 2035 (1.5B Euro 1.0408) 1,554 1,370 3.55% Notes due 2036 885 848 5.95% Notes due 2037 993 1,181 3.625% Notes due 2037 1,381 1,328 3.40% Notes due 2038 992 898 5.85% Debentures due 2038 697 817 4.50% Debentures due 2040 540 546 2.10% Notes due 2040 876 647 4.85% Notes due 2041 297 312 4.50% Notes due 2043 496 506 3.70% Notes due 2046 1,975 1,830 3.75% Notes due 2047 863 806 3.50% Notes due 2048 743 677 2.25% Notes due 2050 864 599 2.45% Notes due 2060 1,108 773 Other 10 10 Total Non-Current Debt $ 28,292 26,781

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	6 Months Ended
	Jul. 03, 2022
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components: Fiscal Second Quarter Ended Fiscal Six Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 Service cost $ 319 327 80 77 640 680 160 154 Interest cost 229 193 27 21 459 386 53 41 Expected return on plan assets (693) (647) (2) (2) (1,392) (1,327) (4) (4) Amortization of prior service cost/(credit) (46) (45) (2) (7) (92) (90) (3) (15) Recognized actuarial losses 167 316 31 37 329 630 61 75 Curtailments and settlements — — — — 1 1 — — Net periodic benefit cost/(credit) $ (24) 144 134 126 (55) 280 267 251

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jul. 03, 2022
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 2, 2022 $ (10,017) (3) (2,702) (336) (13,058) Net change (705) (33) 230 (277) (785) July 3, 2022 $ (10,722) (36) (2,472) (613) (13,843)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jul. 03, 2022
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share: Fiscal Second Quarter Ended Fiscal Six Months Ended (Shares in Millions) July 3, 2022 July 4, 2021 July 3, 2022 July 4, 2021 Basic net earnings per share $ 1.83 2.38 3.79 4.74 Average shares outstanding — basic 2,629.6 2,632.5 2,629.4 2,632.0 Potential shares exercisable under stock option plans 143.7 141.9 141.8 126.0 Less: shares which could be repurchased under treasury stock method (105.4) (102.8) (102.0) (84.0) Average shares outstanding — diluted 2,667.9 2,671.6 2,669.2 2,674.0 Diluted net earnings per share $ 1.80 2.35 3.73 4.67

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	6 Months Ended
	Jul. 03, 2022
Segment Reporting [Abstract]
Sales By Segment Of Business	SALES BY SEGMENT OF BUSINESS Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) July 3, July 4, Percent July 3, July 4, Percent Change CONSUMER HEALTH (1) OTC U.S. $ 663 675 (1.8) % $ 1,333 1,274 4.6 % International 818 752 8.8 1,609 1,425 12.9 Worldwide 1,482 1,426 3.8 2,943 2,699 9.0 Skin Health/Beauty U.S. 629 659 (4.5) 1,173 1,293 (9.2) International 497 511 (2.8) 965 1,040 (7.2) Worldwide 1,126 1,170 (3.7) 2,138 2,333 (8.3) Oral Care U.S. 170 165 3.4 313 328 (4.6) International 224 260 (14.1) 447 514 (13.0) Worldwide 394 426 (7.3) 760 843 (9.7) Baby Care U.S. 88 97 (9.1) 173 193 (10.3) International 287 290 (1.0) 557 583 (4.4) Worldwide 375 387 (3.1) 730 776 (5.9) Women's Health U.S. 3 3 8.9 7 6 8.1 International 228 227 0.1 452 446 1.3 Worldwide 230 230 0.2 458 452 1.4 Wound Care/Other U.S. 133 153 (12.7) 245 268 (8.6) International 65 64 1.7 117 125 (6.6) Worldwide 197 216 (8.4) 361 393 (8.0) TOTAL CONSUMER HEALTH U.S. 1,687 1,751 (3.6) 3,244 3,362 (3.5) International 2,118 2,103 0.6 4,147 4,133 0.3 Worldwide 3,805 3,854 (1.3) 7,391 7,495 (1.4) PHARMACEUTICAL (1) Immunology U.S. 2,853 2,748 3.8 5,354 5,161 3.7 International 1,559 1,483 5.1 3,176 2,984 6.4 Worldwide 4,411 4,231 4.3 8,530 8,145 4.7 REMICADE U.S. 391 540 (27.4) 749 1,029 (27.1) U.S. Exports 44 93 (53.0) 124 150 (17.5) International 212 255 (17.2) 437 487 (10.3) Worldwide 647 888 (27.2) 1,310 1,665 (21.4) SIMPONI / SIMPONI ARIA U.S. 301 290 3.8 588 545 7.9 International 266 294 (9.7) 549 601 (8.6) Worldwide 566 584 (3.0) 1,137 1,146 (0.8) STELARA U.S. 1,731 1,496 15.7 3,110 2,827 10.0 International 868 778 11.6 1,777 1,595 11.4 Worldwide 2,599 2,274 14.3 4,887 4,422 10.5 TREMFYA U.S. 382 325 17.7 773 599 29.1 International 214 155 38.3 413 298 38.6 Worldwide 597 479 24.4 1,187 897 32.3 OTHER IMMUNOLOGY U.S. 3 5 (50.1) 9 12 (24.8) International 0 1 * 0 3 * Worldwide 3 7 (59.2) 9 15 (39.0) Infectious Diseases U.S. 415 444 (6.4) 876 956 (8.3) International 901 575 56.8 1,737 1,060 63.9 Worldwide 1,316 1,018 29.3 2,613 2,016 29.6 COVID-19 VACCINE U.S. 45 51 (11.5) 120 151 (20.4) International 499 113 * 881 113 * Worldwide 544 164 * 1,001 264 * EDURANT / rilpivirine U.S. 9 9 (1.7) 18 19 (7.4) International 215 253 (14.7) 454 486 (6.5) Worldwide 225 262 (14.3) 473 505 (6.5) PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 355 368 (3.4) 724 748 (3.2) International 110 137 (20.2) 242 303 (20.3) Worldwide 464 505 (7.9) 965 1,051 (8.1) OTHER INFECTIOUS DISEASES U.S. 6 16 (62.5) 14 37 (62.5) International 77 71 7.4 160 158 1.3 Worldwide 83 88 (5.4) 174 196 (10.9) Neuroscience U.S. 896 842 6.5 1,739 1,613 7.9 International 837 963 (13.0) 1,735 1,906 (8.9) Worldwide 1,734 1,804 (3.9) 3,475 3,519 (1.2) CONCERTA / methylphenidate U.S. 38 35 9.4 73 82 (11.3) International 123 127 (2.2) 245 250 (1.7) Worldwide 161 161 0.3 318 332 (4.1) INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 691 645 7.3 1,352 1,234 9.6 International 362 380 (4.6) 749 756 (0.8) Worldwide 1,054 1,024 2.9 2,102 1,989 5.7 RISPERDAL CONSTA U.S. 65 72 (8.9) 128 139 (7.7) International 60 84 (28.0) 126 173 (27.1) Worldwide 125 155 (19.3) 254 312 (18.4) OTHER NEUROSCIENCE U.S. 102 91 11.8 186 158 17.6 International 292 373 (21.8) 615 728 (15.5) Worldwide 393 464 (15.2) 800 886 (9.6) Oncology U.S. 1,679 1,462 14.9 3,261 2,839 14.9 International 2,362 2,073 14.0 4,731 4,266 10.9 Worldwide 4,042 3,535 14.3 7,992 7,105 12.5 DARZALEX U.S. 1,021 770 32.6 1,974 1,461 35.1 International 965 663 45.5 1,868 1,337 39.7 Worldwide 1,986 1,433 38.6 3,842 2,798 37.3 ERLEADA U.S. 233 193 20.6 439 364 20.4 International 218 109 * 412 199 * Worldwide 450 302 49.5 850 563 51.1 IMBRUVICA U.S. 349 454 (23.1) 719 898 (19.9) International 620 662 (6.3) 1,288 1,342 (4.0) Worldwide 970 1,116 (13.1) 2,008 2,241 (10.4) ZYTIGA / abiraterone acetate U.S. 19 21 (12.2) 38 71 (47.0) International 486 542 (10.2) 1,006 1,130 (11.0) Worldwide 505 563 (10.3) 1,044 1,201 (13.1) OTHER ONCOLOGY U.S. 57 23 * 91 44 * International 72 97 (25.7) 156 258 (39.4) Worldwide 130 120 7.5 248 302 (18.0) Pulmonary Hypertension U.S. 560 595 (5.8) 1,132 1,168 (3.1) International 284 275 2.8 563 563 (0.1) Worldwide 843 870 (3.1) 1,695 1,731 (2.1) OPSUMIT U.S. 265 290 (8.7) 538 562 (4.3) International 173 172 0.5 343 351 (2.2) Worldwide 438 463 (5.3) 881 913 (3.5) UPTRAVI U.S. 272 268 1.4 541 527 2.6 International 56 45 26.2 112 91 23.5 Worldwide 328 313 4.9 653 618 5.7 OTHER PULMONARY HYPERTENSION U.S. 23 36 (36.2) 53 78 (32.3) International 55 59 (8.1) 108 122 (11.7) Worldwide 78 95 (18.7) 161 200 (19.8) Cardiovascular / Metabolism / Other U.S. 757 780 (3.0) 1,429 1,579 (9.5) International 215 241 (10.9) 453 486 (6.9) Worldwide 972 1,021 (4.8) 1,882 2,065 (8.9) XARELTO U.S. 609 569 7.1 1,117 1,158 (3.5) International — — — — — — Worldwide 609 569 7.1 1,117 1,158 (3.5) INVOKANA / INVOKAMET U.S. 55 96 (42.9) 115 183 (37.1) International 65 64 2.4 133 127 4.9 Worldwide 120 160 (24.9) 248 310 (19.9) OTHER (2) U.S. 93 116 (19.5) 197 238 (17.2) International 150 178 (15.6) 320 360 (11.1) Worldwide 243 293 (17.2) 517 598 (13.5) TOTAL PHARMACEUTICAL U.S. 7,159 6,869 4.2 13,791 13,315 3.6 International 6,158 5,611 9.8 12,395 11,266 10.0 Worldwide 13,317 12,480 6.7 26,186 24,581 6.5 MEDTECH (3) Interventional Solutions U.S. 525 475 10.5 1,019 909 12.1 International 525 572 (8.1) 1,123 1,086 3.4 Worldwide 1,049 1,046 0.3 2,141 1,995 7.4 Orthopaedics U.S. 1,338 1,323 1.1 2,627 2,572 2.1 International 820 904 (9.3) 1,719 1,768 (2.8) Worldwide 2,157 2,227 (3.1) 4,345 4,340 0.1 HIPS U.S. 240 233 3.4 465 442 5.2 International 148 159 (6.6) 312 305 2.4 Worldwide 388 391 (0.7) 777 747 4.1 KNEES U.S. 216 210 2.9 417 395 5.6 International 133 140 (4.6) 271 272 (0.4) Worldwide 349 350 (0.1) 688 667 3.1 TRAUMA U.S. 464 447 3.9 939 897 4.7 International 232 263 (11.8) 505 545 (7.4) Worldwide 696 710 (1.9) 1,444 1,443 0.1 SPINE, SPORTS & OTHER U.S. 418 434 (3.7) 805 838 (3.9) International 306 343 (10.6) 630 646 (2.4) Worldwide 724 777 (6.8) 1,436 1,484 (3.2) Surgery U.S. 992 1,035 (4.1) 1,913 1,933 (1.0) International 1,458 1,487 (2.0) 2,971 2,961 0.3 Worldwide 2,450 2,522 (2.8) 4,884 4,894 (0.2) ADVANCED U.S. 454 459 (1.1) 871 864 0.8 International 702 708 (0.9) 1,431 1,421 0.7 Worldwide 1,156 1,168 (1.0) 2,302 2,286 0.7 GENERAL U.S. 538 576 (6.4) 1,042 1,069 (2.5) International 756 779 (3.0) 1,540 1,540 0.0 Worldwide 1,294 1,354 (4.5) 2,582 2,608 (1.0) Vision U.S. 496 467 6.2 1,017 939 8.3 International 745 716 4.0 1,481 1,389 6.6 Worldwide 1,241 1,183 4.9 2,498 2,328 7.3 CONTACT LENSES / OTHER U.S. 374 352 6.6 774 723 7.2 International 519 517 0.4 1,030 1,003 2.7 Worldwide 894 868 2.9 1,804 1,725 4.5 SURGICAL U.S. 122 115 5.1 243 216 12.1 International 225 199 13.6 451 386 17.0 Worldwide 347 314 10.5 694 602 15.2 TOTAL MEDTECH U.S. 3,351 3,299 1.6 6,576 6,353 3.5 International 3,547 3,679 (3.6) 7,293 7,204 1.2 Worldwide 6,898 6,978 (1.1) 13,869 13,557 2.3 WORLDWIDE U.S. 12,197 11,919 2.3 23,611 23,030 2.5 International 11,823 11,393 3.8 23,835 22,603 5.5 Worldwide $ 24,020 23,312 3.0 % $ 47,446 45,633 4.0 % *Percentage greater than 100% or not meaningful (1) Approximately $0.1 billion in the fiscal second quarter of 2021 and $0.2 billion in the fiscal six months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (2) Inclusive of PROCRIT / EPREX which was previously disclosed separately (3) Previously referred to as Medical Devices
Operating Profit by Segment of Business	EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT* Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) July 3, July 4, Percent July 3, July 4, Percent Consumer Health (1) $ 784 866 (9.5) % $ 1,470 1,708 (13.9) % Pharmaceutical (2) 4,420 4,294 2.9 8,344 9,463 (11.8) MedTech (3) 1,141 1,746 (34.7) 2,618 3,375 (22.4) Segment earnings before provision for taxes 6,345 6,906 (8.1) 12,432 14,546 (14.5) Less: Expense not allocated to segments (4) 237 244 360 455 Less: Consumer Health separation costs 268 — 370 — Worldwide income before tax $ 5,840 6,662 (12.3) % $ 11,702 14,091 (17.0) % *The 2021 fiscal second quarter and six months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (1) Consumer Health includes: • Intangible amortization expense of $0.1 billion in both the fiscal second quarter of 2022 and 2021 and $0.2 billion in both the fiscal six months of 2022 and 2021. • Litigation expense of $0.1 billion in both the fiscal second quarters and fiscal six months of 2022 and 2021, primarily for talc related costs. (2) Pharmaceutical includes: • Divestiture gains of $0.6 billion in the fiscal six months of 2021 related to two brands outside the U.S. • Intangible amortization expense of $0.7 billion and $0.8 billion in the fiscal second quarter of 2022 and 2021, respectively. Intangible amortization expense of $1.5 billion and $1.7 billion in the fiscal six months of 2022 and 2021, respectively. • In the fiscal six months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. • A loss of $0.1 billion and a gain of $0.2 billion related to the change in the fair value of securities in the fiscal second quarter of 2022 and 2021, respectively. A loss of $0.5 billion and a gain of $0.1 billion related to the change in the fair value of securities in the fiscal six months of 2022 and 2021, respectively. • COVID-19 Vaccine supply network related costs of $0.2 billion in both the fiscal second quarter and fiscal six months 2022 In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal second quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.9 billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. (3) MedTech includes: • Litigation expense of $0.3 billion in both the fiscal second quarters and fiscal six months of 2022 primarily pelvic mesh related costs. • A restructuring related charge of $0.2 billion and $0.1 billion in the fiscal six months of 2022 and 2021, respectively. • Intangible amortization expense of $0.3 billion in both the fiscal second quarter of 2022 and 2021 and $0.5 billion in both the fiscal six months of 2022 and 2021.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	SALES BY GEOGRAPHIC AREA Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) July 3, 2022 July 4, 2021 Percent July 3, 2022 July 4, 2021 Percent Change United States $ 12,197 11,919 2.3 % $ 23,611 23,030 2.5 % Europe 6,085 5,668 7.3 12,109 11,082 9.3 Western Hemisphere, excluding U.S. 1,536 1,367 12.4 3,018 2,791 8.1 Asia-Pacific, Africa 4,202 4,358 (3.6) 8,708 8,730 (0.2) Total $ 24,020 23,312 3.0 % $ 47,446 45,633 4.0 %

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jul. 03, 2022
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal second quarter of 2022: (Dollars in Millions) Severance Asset Write-offs/Sales Other (2) Total Reserve balance, January 2, 2022 $ 112 — 25 137 Current year activity: Charges — (11) 211 200 Cash settlements (23) 35 (3) (214) (202) Settled non cash — (24) — (24) Reserve balance, July 3, 2022 (1) $ 89 — 22 111 (1) Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Represents gain on sale of assets

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jul. 03, 2022	Jan. 02, 2022
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 1,696	$ 1,592
Goods in process	2,324	2,287
Finished goods	7,417	6,508
Total inventories	$ 11,437	$ 10,387

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 03, 2022	Jan. 02, 2022
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	$ 15,570	$ 16,822
Total intangible assets - net	42,408	46,392
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	6,794	6,985
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	8,776	9,837
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	36,885	38,572
Less accumulated amortization	(20,336)	(20,088)
Finite-Lived Intangible Assets, Net	16,549	18,484
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	22,558	23,011
Less accumulated amortization	(12,269)	(11,925)
Finite-Lived Intangible Assets, Net	10,289	$ 11,086
In-process research and development | bermekimab
Intangible assets with indefinite lives:
Impairment of intangible assets	$ 600

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill By Segment (Details) $ in Millions	6 Months Ended
	Jul. 03, 2022 USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 35,246
Goodwill, related to acquisitions	195
Currency translation/Other	(1,275)
Goodwill End of Period	34,166
CONSUMER HEALTH (1)
Goodwill [Roll Forward]
Goodwill Beginning of Period	9,810
Goodwill, related to acquisitions	0
Currency translation/Other	(665)
Goodwill End of Period	9,145
PHARMACEUTICAL(1)
Goodwill [Roll Forward]
Goodwill Beginning of Period	10,580
Goodwill, related to acquisitions	0
Currency translation/Other	(545)
Goodwill End of Period	10,035
MedTech
Goodwill [Roll Forward]
Goodwill Beginning of Period	14,856
Goodwill, related to acquisitions	195
Currency translation/Other	(65)
Goodwill End of Period	$ 14,986

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Billions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Finite-Lived Intangible Assets [Line Items]
Amortization expense of amortizable intangible assets	$ 1.1	$ 1.2	$ 2.2	$ 2.4
Patents And Trademarks
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life			12 years
Customer relationships and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Weighted-Average Useful Life			21 years

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details) $ in Millions	Jul. 03, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 4,400
2023	4,400
2024	4,200
2025	3,400
2026	$ 2,800

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Apr. 03, 2022	Jul. 03, 2022	Jan. 02, 2022
Derivative [Line Items]
Accumulated other comprehensive income on derivatives, after tax		$ (613)
Reclassification of foreign exchange contracts into earnings, period		next 12 months
Maximum length of time for hedge exposure		18 months
Weighted average interest rate on non-current debt		3.04%
Excess of the estimated fair value over the carrying value of debt	$ 3,200
Current Debt		$ 4,305	$ 3,766
Commercial Paper
Derivative [Line Items]
Current Debt		$ 3,800
Weighted average interest rate		0.98%
Term		2 months
Forward foreign exchange contracts
Derivative [Line Items]
Collateral already posted, aggregate fair value		$ 233
Derivative, notional amount		46,700	45,800
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, notional amount		37,200	37,400
Interest Rate Swap
Derivative [Line Items]
Derivative, notional amount		10,000	$ 10,000
Equity Investments without readily determinable value | Equity Securities
Derivative [Line Items]
Equity, fair value adjustment, impairment loss		(14)
Changes in Fair Value Reflected in Net Income		$ (14)

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	$ 0	$ 0	$ 0	$ 0
Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			0	0
Amount of gain or (loss) recognized in AOCI			0	0
Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing			89	80
Amount of gain or (loss) recognized in AOCI			89	80
Fair Value Hedging | Interest Rate Swap | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging | Interest Rate Swap | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging | Interest Rate Swap | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging | Interest Rate Swap | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0	0	0
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Fair Value Hedging | Interest Rate Swap | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	(241)	(6)	(772)	(6)
Amount of gain or (loss) recognized in AOCI	241	6	772	6
Net Investment Hedging [Member] | Net Investment Hedging [Member] | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Net Investment Hedging [Member] | Net Investment Hedging [Member] | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Net Investment Hedging [Member] | Net Investment Hedging [Member] | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Net Investment Hedging [Member] | Net Investment Hedging [Member] | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Net Investment Hedging [Member] | Net Investment Hedging [Member] | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	44	40
Amount of gain or (loss) recognized in AOCI	44	40
Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	(25)	(3)	(3)	(6)
Amount of gain or (loss) reclassified from AOCI into income	(17)	11	(34)	28
Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	35	(50)	(59)	(243)
Amount of gain or (loss) reclassified from AOCI into income	(6)	14	(58)	48
Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	69	119	102	43
Amount of gain or (loss) reclassified from AOCI into income	42	104	65	(9)
Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	(38)	8	(111)	25
Amount of gain or (loss) reclassified from AOCI into income	(39)	2	(57)	5
Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0		0	0
Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	0	0	0	0
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in AOCI	60	286	(68)	(21)
Amount of gain or (loss) reclassified from AOCI into income	$ 102	$ 99	$ 222	$ 191

Fair Value Measurements - Deriv

Fair Value Measurements - Derivatives, Balance Sheet Location (Details) - USD ($) $ in Millions	Jul. 03, 2022	Jan. 02, 2022
Derivative [Line Items]
Carrying Amount of the Hedged Liability	$ 3,097	$ 1,888
Long-term Debt | Designated as Hedging Instrument
Derivative [Line Items]
Carrying Amount of the Hedged Liability	9,035	9,793
Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability	$ (1,010)	$ (142)

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Not Designated as Hedging Instrument | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Income on Derivative	$ 73	$ (21)	$ 102	$ (37)

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI	$ 202	$ (45)	$ 270	$ 164
Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0	0	0
Cross Currency Interest Rate Contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI	313	(70)	873	291
Cross Currency Interest Rate Contract | Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	$ 0	$ 0	$ 0	$ 0

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 03, 2022	Jan. 02, 2022
Equity Investment [Roll Forward]
Non Current Other Assets	$ 9,435	$ 10,216
Equity Securities
Equity Investment [Roll Forward]
Carrying value, end of period	600
Equity Securities | Equity Investments with readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	1,884
Changes in Fair Value Reflected in Net Income	(508)
Sales/ Purchases/Other	(36)
Carrying value, end of period	1,340
Non Current Other Assets	1,340
Equity Securities | Equity Investments without readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	500
Changes in Fair Value Reflected in Net Income	(14)
Sales/ Purchases/Other	35
Carrying value, end of period	521
Non Current Other Assets	$ 521

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jan. 02, 2022
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 3,293
Derivatives designated as hedging instruments : Liabilities	3,053
Available-for-sale Securities, Equity Securities	1,340		$ 1,884
Available-for-sale Securities	21,123		19,727
Contingent consideration	536		533
Total Gross Assets	3,340		1,360
Credit Support Agreement (CSA)	(3,226)		(1,285)
Total Net Asset	114		75
Total Gross Liabilities	3,097		1,888
Credit Support Agreement (CSA)	(2,993)		(1,855)
Total Net Liabilities	104		33
Beginning Balance	533	$ 633
Changes in estimated fair value (6)	(88)	8
Additions	91	0
Payments	0	(48)
Ending Balance	536	$ 593
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	1,340		1,884
Available-for-sale Securities	0
Contingent consideration	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	3,293		1,336
Derivatives designated as hedging instruments : Liabilities	3,053		1,860
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	21,123
Contingent consideration	0
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	0
Contingent consideration	536		533
Interest Rate Contract
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,979
Derivatives designated as hedging instruments : Liabilities	1,540
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,979		796
Derivatives designated as hedging instruments : Liabilities	1,540		979
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,314
Derivatives designated as hedging instruments : Liabilities	1,513
Derivatives not designated as hedging instruments : Assets	47
Derivatives not designated as hedging instruments : Liabilities	44
Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,314		540
Derivatives designated as hedging instruments : Liabilities	1,513		881
Derivatives not designated as hedging instruments : Assets	47		24
Derivatives not designated as hedging instruments : Liabilities	44		28
Forward foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Other Noncurrent Liabilities | Auris Health
Financial assets and liabilities at fair value
Contingent consideration	519		520
Other Current Liabilities
Financial assets and liabilities at fair value
Contingent consideration	$ 17		$ 13

Fair Value Measurements - Cash,

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions	Jul. 03, 2022	Jan. 02, 2022
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Estimated Fair Value	$ 21,123	$ 19,727
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	10,983	14,487
Marketable securities	21,585	$ 17,121
Total cash, cash equivalents and current marketable securities, Carrying Amount	32,614
Total cash, cash equivalents and current marketable securities, Unrecognized Loss	(55)
Total cash, cash equivalents and current marketable securities, Estimated Fair Value	32,559
Held-to-maturity Securities
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	11,445
Held-to-maturity Securities, Unrecognized Loss	(9)
Held-to-maturity Securities - Estimated Fair Value	11,436
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	8,704
Marketable securities	2,741
Held-to-maturity Securities | Cash
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	3,337
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	3,337
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	3,337
Marketable securities	0
Held-to-maturity Securities | Non-U.S. sovereign securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	538
Held-to-maturity Securities, Unrecognized Loss	(1)
Held-to-maturity Securities - Estimated Fair Value	537
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	0
Marketable securities	538
Held-to-maturity Securities | U.S. reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,112
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	2,112
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,112
Marketable securities	0
Held-to-maturity Securities | Corporate debt securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,443
Held-to-maturity Securities, Unrecognized Loss	(8)
Held-to-maturity Securities - Estimated Fair Value	2,435
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	240
Marketable securities	2,203
Held-to-maturity Securities | Money market funds
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	1,968
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	1,968
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	1,968
Marketable securities	0
Held-to-maturity Securities | Time deposits(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	1,047
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	1,047
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	1,047
Marketable securities	0
Available-for-sale Securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	21,169
Available-for-sale Securities, Unrecognized Loss	(46)
Available-for-sale Securities - Estimated Fair Value	21,123
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,279
Marketable securities	18,844
Available-for-sale Securities | Non-U.S. sovereign securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	3
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	3
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	0
Marketable securities	3
Available-for-sale Securities | Corporate debt securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	247
Available-for-sale Securities, Unrecognized Loss	(1)
Available-for-sale Securities - Estimated Fair Value	246
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	28
Marketable securities	218
Available-for-sale Securities | U.S. Gov't securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	20,919
Available-for-sale Securities, Unrecognized Loss	(45)
Available-for-sale Securities - Estimated Fair Value	20,874
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,251
Marketable securities	$ 18,623

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details) $ in Millions	Jul. 03, 2022 USD ($)
Cost Basis
Due within one year	$ 21,155
Due after one year through five years	14
Due after five years through ten years	0
Total debt securities	21,169
Fair Value
Due within one year	21,109
Due after one year through five years	14
Due after five years through ten years	0
Total debt securities	$ 21,123

Fair Value Measurements - Fin_2

Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)	Jul. 03, 2022 USD ($)	Jul. 03, 2022 EUR (€)	Jul. 03, 2022 GBP (£)	Jan. 02, 2022 USD ($)
Financial Liabilities
Current Debt	$ 4,305,000,000			$ 3,766,000,000
Non-Current Debt
Non-Current Debt	28,292,000,000			$ 29,985,000,000
Carrying Amount
Financial Liabilities
Current Debt	4,305,000,000
Non-Current Debt
Non-Current Debt	28,292,000,000
Estimated Fair Value
Financial Liabilities
Current Debt	4,304,000,000
Non-Current Debt
Non-Current Debt	$ 26,781,000,000
6.73% Debentures due 2023
Non-Current Debt
Stated interest rate (as a percent)	6.73%	6.73%	6.73%
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 250,000,000
6.73% Debentures due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 263,000,000
3.375% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	3.375%	3.375%	3.375%
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 802,000,000
3.375% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 805,000,000
0.650% Notes due 2024 (750MM Euro 1.0408)
Non-Current Debt
Stated interest rate (as a percent)	0.65%	0.65%	0.65%
Debt instrument, face amount | €		€ 750,000,000
Foreign exchange rate	1.0408	1.0408	1.0408
0.650% Notes due 2024 (750MM Euro 1.0408) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 774,000,000
0.650% Notes due 2024 (750MM Euro 1.0408) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 766,000,000
5.50% Notes due 2024 (500MM GBP 1.2143)
Non-Current Debt
Stated interest rate (as a percent)	5.50%	5.50%	5.50%
Debt instrument, face amount | £			£ 500,000,000
Foreign exchange rate	1.2143	1.2143	1.2143
5.50% Notes due 2024 (500MM GBP 1.2143) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 605,000,000
5.50% Notes due 2024 (500MM GBP 1.2143) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 647,000,000
2.625% Notes due 2025
Non-Current Debt
Stated interest rate (as a percent)	2.625%	2.625%	2.625%
2.625% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 749,000,000
2.625% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	745,000,000
0.55% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	940,000,000
0.55% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 872,000,000
2.45% Notes due 2026
Non-Current Debt
Stated interest rate (as a percent)	2.45%	2.45%	2.45%
2.45% Notes due 2026 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,995,000,000
2.45% Notes due 2026 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,950,000,000
2.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	2.95%	2.95%	2.95%
2.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 911,000,000
2.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 899,000,000
0.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	0.95%	0.95%	0.95%
0.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,423,000,000
0.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,264,000,000
2.90% Notes due 2028
Non-Current Debt
Stated interest rate (as a percent)	2.90%	2.90%	2.90%
2.90% Notes due 2028 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,496,000,000
2.90% Notes due 2028 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,462,000,000
1.150% Notes due 2028 (750MM Euro 1.0408)
Non-Current Debt
Stated interest rate (as a percent)	1.15%	1.15%	1.15%
Debt instrument, face amount | €		€ 750,000,000
Foreign exchange rate	1.0408	1.0408	1.0408
1.150% Notes due 2028 (750MM Euro 1.0408) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 776,000,000
1.150% Notes due 2028 (750MM Euro 1.0408) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 735,000,000
6.95% Notes due 2029
Non-Current Debt
Stated interest rate (as a percent)	6.95%	6.95%	6.95%
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 298,000,000
6.95% Notes due 2029 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 372,000,000
1.30% Notes due 2030
Non-Current Debt
Stated interest rate (as a percent)	1.30%	1.30%	1.30%
1.30% Notes due 2030 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,646,000,000
1.30% Notes due 2030 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,404,000,000
4.95% Debentures due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.95%	4.95%	4.95%
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 498,000,000
4.95% Debentures due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 554,000,000
4.375% Notes due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.375%	4.375%	4.375%
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 855,000,000
4.375% Notes due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	895,000,000
1.650% Notes due 2035 (1.5B Euro 1.0408) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,554,000,000
Stated interest rate (as a percent)	1.65%	1.65%	1.65%
Debt instrument, face amount	$ 1,500,000,000
Foreign exchange rate	1.0408	1.0408	1.0408
1.650% Notes due 2035 (1.5B Euro 1.0408) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,370,000,000
3.55% Notes due 2036
Non-Current Debt
Stated interest rate (as a percent)	3.55%	3.55%	3.55%
3.55% Notes due 2036 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 885,000,000
3.55% Notes due 2036 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 848,000,000
5.95% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	5.95%	5.95%	5.95%
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 993,000,000
5.95% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,181,000,000
3.625% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	3.625%	3.625%	3.625%
3.625% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,381,000,000
3.625% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,328,000,000
3.40% Notes due 2038
Non-Current Debt
Stated interest rate (as a percent)	3.40%	3.40%	3.40%
3.40% Notes due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 992,000,000
3.40% Notes due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 898,000,000
5.85% Debentures due 2038
Non-Current Debt
Stated interest rate (as a percent)	5.85%	5.85%	5.85%
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 697,000,000
5.85% Debentures due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 817,000,000
4.50% Debentures due 2040
Non-Current Debt
Stated interest rate (as a percent)	4.50%	4.50%	4.50%
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 540,000,000
4.50% Debentures due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 546,000,000
2.10% Notes due 2040
Non-Current Debt
Stated interest rate (as a percent)	2.10%	2.10%	2.10%
2.10% Notes due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 876,000,000
2.10% Notes due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 647,000,000
4.85% Notes due 2041
Non-Current Debt
Stated interest rate (as a percent)	4.85%	4.85%	4.85%
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297,000,000
4.85% Notes due 2041 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 312,000,000
4.50% Notes due 2043
Non-Current Debt
Stated interest rate (as a percent)	4.50%	4.50%	4.50%
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 496,000,000
4.50% Notes due 2043 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 506,000,000
3.70% Notes due 2046
Non-Current Debt
Stated interest rate (as a percent)	3.70%	3.70%	3.70%
3.70% Notes due 2046 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,975,000,000
3.70% Notes due 2046 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,830,000,000
3.75% Notes due 2047
Non-Current Debt
Stated interest rate (as a percent)	3.75%	3.75%	3.75%
3.75% Notes due 2047 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 863,000,000
3.75% Notes due 2047 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 806,000,000
3.50% Notes due 2048
Non-Current Debt
Stated interest rate (as a percent)	3.50%	3.50%	3.50%
3.50% Notes due 2048 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 743,000,000
3.50% Notes due 2048 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 677,000,000
2.25% Notes due 2050
Non-Current Debt
Stated interest rate (as a percent)	2.25%	2.25%	2.25%
2.25% Notes due 2050 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 864,000,000
2.25% Notes due 2050 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 599,000,000
2.45% Notes due 2060
Non-Current Debt
Stated interest rate (as a percent)	2.45%	2.45%	2.45%
2.45% Notes due 2060 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,108,000,000
2.45% Notes due 2060 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	773,000,000
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	10,000,000
Other | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 10,000,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Billions	1 Months Ended	6 Months Ended
	Jul. 29, 2022	Jul. 03, 2022	Jul. 04, 2021
Income Tax Disclosure [Abstract]
Worldwide effective income tax rate (as a percent)		14.90%	11.50%
Deferred tax asset			$ 2.3
Deferred tax liability			1.7
Deferred tax benefit, net			$ 0.6
Decrease in effective tax rate (percent)			4.40%
Unrecognized tax benefits		$ 3.4
Subsequent Event
Income Tax Contingency [Line Items]
Incremental tax costs related to restructuring	$ 0.3

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 319	$ 327	$ 640	$ 680
Interest cost	229	193	459	386
Expected return on plan assets	(693)	(647)	(1,392)	(1,327)
Amortization of prior service cost/(credit)	(46)	(45)	(92)	(90)
Recognized actuarial losses	167	316	329	630
Curtailments and settlements	0	0	1	1
Net periodic benefit cost	(24)	144	(55)	280
Other Benefit Plans
Components of net periodic benefit cost
Service cost	80	77	160	154
Interest cost	27	21	53	41
Expected return on plan assets	(2)	(2)	(4)	(4)
Amortization of prior service cost/(credit)	(2)	(7)	(3)	(15)
Recognized actuarial losses	31	37	61	75
Curtailments and settlements	0	0	0	0
Net periodic benefit cost	$ 134	$ 126	$ 267	$ 251

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans (Details) $ in Millions	6 Months Ended
	Jul. 03, 2022 USD ($)
U.S.
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 54
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 10

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 74,709	$ 65,834	$ 74,023	$ 63,278
Net change	(86)	228	(785)	142
Ending Balance	76,357	69,580	76,357	69,580
Accumulated Foreign Currency Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(10,017)
Ending Balance	(10,722)		(10,722)
Accumulated Net Investment Gain (Loss) Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(3)
Ending Balance	(36)		(36)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(2,702)
Ending Balance	(2,472)		(2,472)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(336)
Ending Balance	(613)		(613)
AOCI Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(13,757)	(15,328)	(13,058)	(15,242)
Net change	(86)	228	(785)	142
Ending Balance	$ (13,843)	$ (15,100)	$ (13,843)	$ (15,100)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares shares in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 1.83	$ 2.38	$ 3.79	$ 4.74
Average shares outstanding — basic	2,629.6	2,632.5	2,629.4	2,632
Potential shares exercisable under stock option plans	143.7	141.9	141.8	126
Less: shares which could be repurchased under treasury stock method	(105.4)	(102.8)	(102)	(84)
Average shares outstanding — diluted	2,667.9	2,671.6	2,669.2	2,674
Diluted net earnings per share	$ 1.80	$ 2.35	$ 3.73	$ 4.67
Antidilutive securities excluded from computation of earnings per share, amount				14

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Sales by segment of business
Sales to customers	$ 24,020	$ 23,312	$ 47,446	$ 45,633
Percent Change (as a percent)	3%		4%
U.S.
Sales by segment of business
Sales to customers	$ 12,197	11,919	$ 23,611	23,030
Percent Change (as a percent)	2.30%		2.50%
International
Sales by segment of business
Sales to customers	$ 11,823	11,393	$ 23,835	22,603
Percent Change (as a percent)	3.80%		5.50%
CONSUMER HEALTH (1)
Sales by segment of business
Sales to customers	$ 3,805	3,854	$ 7,391	7,495
Percent Change (as a percent)	(1.30%)		(1.40%)
CONSUMER HEALTH (1) | U.S.
Sales by segment of business
Sales to customers	$ 1,687	1,751	$ 3,244	3,362
Percent Change (as a percent)	(3.60%)		(3.50%)
CONSUMER HEALTH (1) | International
Sales by segment of business
Sales to customers	$ 2,118	2,103	$ 4,147	4,133
Percent Change (as a percent)	0.60%		0.30%
CONSUMER HEALTH (1) | OTC [Member]
Sales by segment of business
Sales to customers	$ 1,482	1,426	$ 2,943	2,699
Percent Change (as a percent)	3.80%		9%
CONSUMER HEALTH (1) | OTC [Member] | U.S.
Sales by segment of business
Sales to customers	$ 663	675	$ 1,333	1,274
Percent Change (as a percent)	(1.80%)		4.60%
CONSUMER HEALTH (1) | OTC [Member] | International
Sales by segment of business
Sales to customers	$ 818	752	$ 1,609	1,425
Percent Change (as a percent)	8.80%		12.90%
CONSUMER HEALTH (1) | Skin Health/Beauty
Sales by segment of business
Sales to customers	$ 1,126	1,170	$ 2,138	2,333
Percent Change (as a percent)	(3.70%)		(8.30%)
CONSUMER HEALTH (1) | Skin Health/Beauty | U.S.
Sales by segment of business
Sales to customers	$ 629	659	$ 1,173	1,293
Percent Change (as a percent)	(4.50%)		(9.20%)
CONSUMER HEALTH (1) | Skin Health/Beauty | International
Sales by segment of business
Sales to customers	$ 497	511	$ 965	1,040
Percent Change (as a percent)	(2.80%)		(7.20%)
CONSUMER HEALTH (1) | Oral Care
Sales by segment of business
Sales to customers	$ 394	426	$ 760	843
Percent Change (as a percent)	(7.30%)		(9.70%)
CONSUMER HEALTH (1) | Oral Care | U.S.
Sales by segment of business
Sales to customers	$ 170	165	$ 313	328
Percent Change (as a percent)	3.40%		(4.60%)
CONSUMER HEALTH (1) | Oral Care | International
Sales by segment of business
Sales to customers	$ 224	260	$ 447	514
Percent Change (as a percent)	(14.10%)		(13.00%)
CONSUMER HEALTH (1) | Baby Care
Sales by segment of business
Sales to customers	$ 375	387	$ 730	776
Percent Change (as a percent)	(3.10%)		(5.90%)
CONSUMER HEALTH (1) | Baby Care | U.S.
Sales by segment of business
Sales to customers	$ 88	97	$ 173	193
Percent Change (as a percent)	(9.10%)		(10.30%)
CONSUMER HEALTH (1) | Baby Care | International
Sales by segment of business
Sales to customers	$ 287	290	$ 557	583
Percent Change (as a percent)	(1.00%)		(4.40%)
CONSUMER HEALTH (1) | Women's Health
Sales by segment of business
Sales to customers	$ 230	230	$ 458	452
Percent Change (as a percent)	0.20%		1.40%
CONSUMER HEALTH (1) | Women's Health | U.S.
Sales by segment of business
Sales to customers	$ 3	3	$ 7	6
Percent Change (as a percent)	8.90%		8.10%
CONSUMER HEALTH (1) | Women's Health | International
Sales by segment of business
Sales to customers	$ 228	227	$ 452	446
Percent Change (as a percent)	0.10%		1.30%
CONSUMER HEALTH (1) | Wound Care/Other
Sales by segment of business
Sales to customers	$ 197	216	$ 361	393
Percent Change (as a percent)	(8.40%)		(8.00%)
CONSUMER HEALTH (1) | Wound Care/Other | U.S.
Sales by segment of business
Sales to customers	$ 133	153	$ 245	268
Percent Change (as a percent)	(12.70%)		(8.60%)
CONSUMER HEALTH (1) | Wound Care/Other | International
Sales by segment of business
Sales to customers	$ 65	64	$ 117	125
Percent Change (as a percent)	1.70%		(6.60%)
PHARMACEUTICAL(1)
Sales by segment of business
Sales to customers	$ 13,317	12,480	$ 26,186	24,581
Percent Change (as a percent)	6.70%		6.50%
PHARMACEUTICAL(1) | U.S.
Sales by segment of business
Sales to customers	$ 7,159	6,869	$ 13,791	13,315
Percent Change (as a percent)	4.20%		3.60%
PHARMACEUTICAL(1) | International
Sales by segment of business
Sales to customers	$ 6,158	5,611	$ 12,395	11,266
Percent Change (as a percent)	9.80%		10%
PHARMACEUTICAL(1) | Immunology
Sales by segment of business
Sales to customers	$ 4,411	4,231	$ 8,530	8,145
Percent Change (as a percent)	4.30%		4.70%
PHARMACEUTICAL(1) | Immunology | U.S.
Sales by segment of business
Sales to customers	$ 2,853	2,748	$ 5,354	5,161
Percent Change (as a percent)	3.80%		3.70%
PHARMACEUTICAL(1) | Immunology | International
Sales by segment of business
Sales to customers	$ 1,559	1,483	$ 3,176	2,984
Percent Change (as a percent)	5.10%		6.40%
PHARMACEUTICAL(1) | Immunology | REMICADE
Sales by segment of business
Sales to customers	$ 647	888	$ 1,310	1,665
Percent Change (as a percent)	(27.20%)		(21.40%)
PHARMACEUTICAL(1) | Immunology | REMICADE | U.S.
Sales by segment of business
Sales to customers	$ 391	540	$ 749	1,029
Percent Change (as a percent)	(27.40%)		(27.10%)
PHARMACEUTICAL(1) | Immunology | REMICADE | U.S. Exports
Sales by segment of business
Sales to customers	$ 44	93	$ 124	150
Percent Change (as a percent)	(53.00%)		(17.50%)
PHARMACEUTICAL(1) | Immunology | REMICADE | International
Sales by segment of business
Sales to customers	$ 212	255	$ 437	487
Percent Change (as a percent)	(17.20%)		(10.30%)
PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA
Sales by segment of business
Sales to customers	$ 566	584	$ 1,137	1,146
Percent Change (as a percent)	(3.00%)		(0.80%)
PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA | U.S.
Sales by segment of business
Sales to customers	$ 301	290	$ 588	545
Percent Change (as a percent)	3.80%		7.90%
PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA | International
Sales by segment of business
Sales to customers	$ 266	294	$ 549	601
Percent Change (as a percent)	(9.70%)		(8.60%)
PHARMACEUTICAL(1) | Immunology | STELARA
Sales by segment of business
Sales to customers	$ 2,599	2,274	$ 4,887	4,422
Percent Change (as a percent)	14.30%		10.50%
PHARMACEUTICAL(1) | Immunology | STELARA | U.S.
Sales by segment of business
Sales to customers	$ 1,731	1,496	$ 3,110	2,827
Percent Change (as a percent)	15.70%		10%
PHARMACEUTICAL(1) | Immunology | STELARA | International
Sales by segment of business
Sales to customers	$ 868	778	$ 1,777	1,595
Percent Change (as a percent)	11.60%		11.40%
PHARMACEUTICAL(1) | Immunology | TREMFYA
Sales by segment of business
Sales to customers	$ 597	479	$ 1,187	897
Percent Change (as a percent)	24.40%		32.30%
PHARMACEUTICAL(1) | Immunology | TREMFYA | U.S.
Sales by segment of business
Sales to customers	$ 382	325	$ 773	599
Percent Change (as a percent)	17.70%		29.10%
PHARMACEUTICAL(1) | Immunology | TREMFYA | International
Sales by segment of business
Sales to customers	$ 214	155	$ 413	298
Percent Change (as a percent)	38.30%		38.60%
PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY
Sales by segment of business
Sales to customers	$ 3	7	$ 9	15
Percent Change (as a percent)	(59.20%)		(39.00%)
PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY | U.S.
Sales by segment of business
Sales to customers	$ 3	5	$ 9	12
Percent Change (as a percent)	(50.10%)		(24.80%)
PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY | International
Sales by segment of business
Sales to customers	$ 0	1	$ 0	3
PHARMACEUTICAL(1) | Infectious Diseases
Sales by segment of business
Sales to customers	$ 1,316	1,018	$ 2,613	2,016
Percent Change (as a percent)	29.30%		29.60%
PHARMACEUTICAL(1) | Infectious Diseases | U.S.
Sales by segment of business
Sales to customers	$ 415	444	$ 876	956
Percent Change (as a percent)	(6.40%)		(8.30%)
PHARMACEUTICAL(1) | Infectious Diseases | International
Sales by segment of business
Sales to customers	$ 901	575	$ 1,737	1,060
Percent Change (as a percent)	56.80%		63.90%
PHARMACEUTICAL(1) | Infectious Diseases | COVID-19
Sales by segment of business
Sales to customers	$ 544	164	$ 1,001	264
PHARMACEUTICAL(1) | Infectious Diseases | COVID-19 | U.S.
Sales by segment of business
Sales to customers	$ 45	51	$ 120	151
Percent Change (as a percent)	(11.50%)		(20.40%)
PHARMACEUTICAL(1) | Infectious Diseases | COVID-19 | International
Sales by segment of business
Sales to customers	$ 499	113	$ 881	113
PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine
Sales by segment of business
Sales to customers	$ 225	262	$ 473	505
Percent Change (as a percent)	(14.30%)		(6.50%)
PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine | U.S.
Sales by segment of business
Sales to customers	$ 9	9	$ 18	19
Percent Change (as a percent)	(1.70%)		(7.40%)
PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine | International
Sales by segment of business
Sales to customers	$ 215	253	$ 454	486
Percent Change (as a percent)	(14.70%)		(6.50%)
PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
Sales by segment of business
Sales to customers	$ 464	505	$ 965	1,051
Percent Change (as a percent)	(7.90%)		(8.10%)
PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S.
Sales by segment of business
Sales to customers	$ 355	368	$ 724	748
Percent Change (as a percent)	(3.40%)		(3.20%)
PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International
Sales by segment of business
Sales to customers	$ 110	137	$ 242	303
Percent Change (as a percent)	(20.20%)		(20.30%)
PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES(
Sales by segment of business
Sales to customers	$ 83	88	$ 174	196
Percent Change (as a percent)	(5.40%)		(10.90%)
PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S.
Sales by segment of business
Sales to customers	$ 6	16	$ 14	37
Percent Change (as a percent)	(62.50%)		(62.50%)
PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International
Sales by segment of business
Sales to customers	$ 77	71	$ 160	158
Percent Change (as a percent)	7.40%		1.30%
PHARMACEUTICAL(1) | Neuroscience
Sales by segment of business
Sales to customers	$ 1,734	1,804	$ 3,475	3,519
Percent Change (as a percent)	(3.90%)		(1.20%)
PHARMACEUTICAL(1) | Neuroscience | U.S.
Sales by segment of business
Sales to customers	$ 896	842	$ 1,739	1,613
Percent Change (as a percent)	6.50%		7.90%
PHARMACEUTICAL(1) | Neuroscience | International
Sales by segment of business
Sales to customers	$ 837	963	$ 1,735	1,906
Percent Change (as a percent)	(13.00%)		(8.90%)
PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate
Sales by segment of business
Sales to customers	$ 161	161	$ 318	332
Percent Change (as a percent)	0.30%		(4.10%)
PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate | U.S.
Sales by segment of business
Sales to customers	$ 38	35	$ 73	82
Percent Change (as a percent)	9.40%		(11.30%)
PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate | International
Sales by segment of business
Sales to customers	$ 123	127	$ 245	250
Percent Change (as a percent)	(2.20%)		(1.70%)
PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
Sales by segment of business
Sales to customers	$ 1,054	1,024	$ 2,102	1,989
Percent Change (as a percent)	2.90%		5.70%
PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S.
Sales by segment of business
Sales to customers	$ 691	645	$ 1,352	1,234
Percent Change (as a percent)	7.30%		9.60%
PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International
Sales by segment of business
Sales to customers	$ 362	380	$ 749	756
Percent Change (as a percent)	(4.60%)		(0.80%)
PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA
Sales by segment of business
Sales to customers	$ 125	155	$ 254	312
Percent Change (as a percent)	(19.30%)		(18.40%)
PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA | U.S.
Sales by segment of business
Sales to customers	$ 65	72	$ 128	139
Percent Change (as a percent)	(8.90%)		(7.70%)
PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA | International
Sales by segment of business
Sales to customers	$ 60	84	$ 126	173
Percent Change (as a percent)	(28.00%)		(27.10%)
PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE
Sales by segment of business
Sales to customers	$ 393	464	$ 800	886
Percent Change (as a percent)	(15.20%)		(9.60%)
PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE | U.S.
Sales by segment of business
Sales to customers	$ 102	91	$ 186	158
Percent Change (as a percent)	11.80%		17.60%
PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE | International
Sales by segment of business
Sales to customers	$ 292	373	$ 615	728
Percent Change (as a percent)	(21.80%)		(15.50%)
PHARMACEUTICAL(1) | Oncology
Sales by segment of business
Sales to customers	$ 4,042	3,535	$ 7,992	7,105
Percent Change (as a percent)	14.30%		12.50%
PHARMACEUTICAL(1) | Oncology | U.S.
Sales by segment of business
Sales to customers	$ 1,679	1,462	$ 3,261	2,839
Percent Change (as a percent)	14.90%		14.90%
PHARMACEUTICAL(1) | Oncology | International
Sales by segment of business
Sales to customers	$ 2,362	2,073	$ 4,731	4,266
Percent Change (as a percent)	14%		10.90%
PHARMACEUTICAL(1) | Oncology | DARZALEX
Sales by segment of business
Sales to customers	$ 1,986	1,433	$ 3,842	2,798
Percent Change (as a percent)	38.60%		37.30%
PHARMACEUTICAL(1) | Oncology | DARZALEX | U.S.
Sales by segment of business
Sales to customers	$ 1,021	770	$ 1,974	1,461
Percent Change (as a percent)	32.60%		35.10%
PHARMACEUTICAL(1) | Oncology | DARZALEX | International
Sales by segment of business
Sales to customers	$ 965	663	$ 1,868	1,337
Percent Change (as a percent)	45.50%		39.70%
PHARMACEUTICAL(1) | Oncology | ERLEADA
Sales by segment of business
Sales to customers	$ 450	302	$ 850	563
Percent Change (as a percent)	49.50%		51.10%
PHARMACEUTICAL(1) | Oncology | ERLEADA | U.S.
Sales by segment of business
Sales to customers	$ 233	193	$ 439	364
Percent Change (as a percent)	20.60%		20.40%
PHARMACEUTICAL(1) | Oncology | ERLEADA | International
Sales by segment of business
Sales to customers	$ 218	109	$ 412	199
PHARMACEUTICAL(1) | Oncology | IMBRUVICA
Sales by segment of business
Sales to customers	$ 970	1,116	$ 2,008	2,241
Percent Change (as a percent)	(13.10%)		(10.40%)
PHARMACEUTICAL(1) | Oncology | IMBRUVICA | U.S.
Sales by segment of business
Sales to customers	$ 349	454	$ 719	898
Percent Change (as a percent)	(23.10%)		(19.90%)
PHARMACEUTICAL(1) | Oncology | IMBRUVICA | International
Sales by segment of business
Sales to customers	$ 620	662	$ 1,288	1,342
Percent Change (as a percent)	(6.30%)		(4.00%)
PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate
Sales by segment of business
Sales to customers	$ 505	563	$ 1,044	1,201
Percent Change (as a percent)	(10.30%)		(13.10%)
PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate | U.S.
Sales by segment of business
Sales to customers	$ 19	21	$ 38	71
Percent Change (as a percent)	(12.20%)		(47.00%)
PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate | International
Sales by segment of business
Sales to customers	$ 486	542	$ 1,006	1,130
Percent Change (as a percent)	(10.20%)		(11.00%)
PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY
Sales by segment of business
Sales to customers	$ 130	120	$ 248	302
Percent Change (as a percent)	7.50%		(18.00%)
PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY | U.S.
Sales by segment of business
Sales to customers	$ 57	23	$ 91	44
PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY | International
Sales by segment of business
Sales to customers	$ 72	97	$ 156	258
Percent Change (as a percent)	(25.70%)		(39.40%)
PHARMACEUTICAL(1) | Pulmonary Hypertension
Sales by segment of business
Sales to customers	$ 843	870	$ 1,695	1,731
Percent Change (as a percent)	(3.10%)		(2.10%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | U.S.
Sales by segment of business
Sales to customers	$ 560	595	$ 1,132	1,168
Percent Change (as a percent)	(5.80%)		(3.10%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | International
Sales by segment of business
Sales to customers	$ 284	275	$ 563	563
Percent Change (as a percent)	2.80%		(0.10%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT
Sales by segment of business
Sales to customers	$ 438	463	$ 881	913
Percent Change (as a percent)	(5.30%)		(3.50%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT | U.S.
Sales by segment of business
Sales to customers	$ 265	290	$ 538	562
Percent Change (as a percent)	(8.70%)		(4.30%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT | International
Sales by segment of business
Sales to customers	$ 173	172	$ 343	351
Percent Change (as a percent)	0.50%		(2.20%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI
Sales by segment of business
Sales to customers	$ 328	313	$ 653	618
Percent Change (as a percent)	4.90%		5.70%
PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI | U.S.
Sales by segment of business
Sales to customers	$ 272	268	$ 541	527
Percent Change (as a percent)	1.40%		2.60%
PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI | International
Sales by segment of business
Sales to customers	$ 56	45	$ 112	91
Percent Change (as a percent)	26.20%		23.50%
PHARMACEUTICAL(1) | Pulmonary Hypertension | Other
Sales by segment of business
Sales to customers	$ 78	95	$ 161	200
Percent Change (as a percent)	(18.70%)		(19.80%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | Other | U.S.
Sales by segment of business
Sales to customers	$ 23	36	$ 53	78
Percent Change (as a percent)	(36.20%)		(32.30%)
PHARMACEUTICAL(1) | Pulmonary Hypertension | Other | International
Sales by segment of business
Sales to customers	$ 55	59	$ 108	122
Percent Change (as a percent)	(8.10%)		(11.70%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other
Sales by segment of business
Sales to customers	$ 972	1,021	$ 1,882	2,065
Percent Change (as a percent)	(4.80%)		(8.90%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | U.S.
Sales by segment of business
Sales to customers	$ 757	780	$ 1,429	1,579
Percent Change (as a percent)	(3.00%)		(9.50%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | International
Sales by segment of business
Sales to customers	$ 215	241	$ 453	486
Percent Change (as a percent)	(10.90%)		(6.90%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO
Sales by segment of business
Sales to customers	$ 609	569	$ 1,117	1,158
Percent Change (as a percent)	7.10%		(3.50%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO | U.S.
Sales by segment of business
Sales to customers	$ 609	569	$ 1,117	1,158
Percent Change (as a percent)	7.10%		(3.50%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO | International
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0%		0%
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET
Sales by segment of business
Sales to customers	$ 120	160	$ 248	310
Percent Change (as a percent)	(24.90%)		(19.90%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | U.S.
Sales by segment of business
Sales to customers	$ 55	96	$ 115	183
Percent Change (as a percent)	(42.90%)		(37.10%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | International
Sales by segment of business
Sales to customers	$ 65	64	$ 133	127
Percent Change (as a percent)	2.40%		4.90%
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other
Sales by segment of business
Sales to customers	$ 243	293	$ 517	598
Percent Change (as a percent)	(17.20%)		(13.50%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other | U.S.
Sales by segment of business
Sales to customers	$ 93	116	$ 197	238
Percent Change (as a percent)	(19.50%)		(17.20%)
PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other | International
Sales by segment of business
Sales to customers	$ 150	178	$ 320	360
Percent Change (as a percent)	(15.60%)		(11.10%)
MEDTECH(3)
Sales by segment of business
Sales to customers	$ 6,898	6,978	$ 13,869	13,557
Percent Change (as a percent)	(1.10%)		2.30%
MEDTECH(3) | U.S.
Sales by segment of business
Sales to customers	$ 3,351	3,299	$ 6,576	6,353
Percent Change (as a percent)	1.60%		3.50%
MEDTECH(3) | International
Sales by segment of business
Sales to customers	$ 3,547	3,679	$ 7,293	7,204
Percent Change (as a percent)	(3.60%)		1.20%
MEDTECH(3) | Interventional Solutions
Sales by segment of business
Sales to customers	$ 1,049	1,046	$ 2,141	1,995
Percent Change (as a percent)	0.30%		7.40%
MEDTECH(3) | Interventional Solutions | U.S.
Sales by segment of business
Sales to customers	$ 525	475	$ 1,019	909
Percent Change (as a percent)	10.50%		12.10%
MEDTECH(3) | Interventional Solutions | International
Sales by segment of business
Sales to customers	$ 525	572	$ 1,123	1,086
Percent Change (as a percent)	(8.10%)		3.40%
MEDTECH(3) | Orthopaedics
Sales by segment of business
Sales to customers	$ 2,157	2,227	$ 4,345	4,340
Percent Change (as a percent)	(3.10%)		0.10%
MEDTECH(3) | Orthopaedics | U.S.
Sales by segment of business
Sales to customers	$ 1,338	1,323	$ 2,627	2,572
Percent Change (as a percent)	1.10%		2.10%
MEDTECH(3) | Orthopaedics | International
Sales by segment of business
Sales to customers	$ 820	904	$ 1,719	1,768
Percent Change (as a percent)	(9.30%)		(2.80%)
MEDTECH(3) | Orthopaedics | HIPS
Sales by segment of business
Sales to customers	$ 388	391	$ 777	747
Percent Change (as a percent)	(0.70%)		4.10%
MEDTECH(3) | Orthopaedics | HIPS | U.S.
Sales by segment of business
Sales to customers	$ 240	233	$ 465	442
Percent Change (as a percent)	3.40%		5.20%
MEDTECH(3) | Orthopaedics | HIPS | International
Sales by segment of business
Sales to customers	$ 148	159	$ 312	305
Percent Change (as a percent)	(6.60%)		2.40%
MEDTECH(3) | Orthopaedics | KNEES
Sales by segment of business
Sales to customers	$ 349	350	$ 688	667
Percent Change (as a percent)	(0.10%)		3.10%
MEDTECH(3) | Orthopaedics | KNEES | U.S.
Sales by segment of business
Sales to customers	$ 216	210	$ 417	395
Percent Change (as a percent)	2.90%		5.60%
MEDTECH(3) | Orthopaedics | KNEES | International
Sales by segment of business
Sales to customers	$ 133	140	$ 271	272
Percent Change (as a percent)	(4.60%)		(0.40%)
MEDTECH(3) | Orthopaedics | TRAUMA
Sales by segment of business
Sales to customers	$ 696	710	$ 1,444	1,443
Percent Change (as a percent)	(1.90%)		0.10%
MEDTECH(3) | Orthopaedics | TRAUMA | U.S.
Sales by segment of business
Sales to customers	$ 464	447	$ 939	897
Percent Change (as a percent)	3.90%		4.70%
MEDTECH(3) | Orthopaedics | TRAUMA | International
Sales by segment of business
Sales to customers	$ 232	263	$ 505	545
Percent Change (as a percent)	(11.80%)		(7.40%)
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER
Sales by segment of business
Sales to customers	$ 724	777	$ 1,436	1,484
Percent Change (as a percent)	(6.80%)		(3.20%)
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER | U.S.
Sales by segment of business
Sales to customers	$ 418	434	$ 805	838
Percent Change (as a percent)	(3.70%)		(3.90%)
MEDTECH(3) | Orthopaedics | SPINE, SPORTS & OTHER | International
Sales by segment of business
Sales to customers	$ 306	343	$ 630	646
Percent Change (as a percent)	(10.60%)		(2.40%)
MEDTECH(3) | Surgery
Sales by segment of business
Sales to customers	$ 2,450	2,522	$ 4,884	4,894
Percent Change (as a percent)	(2.80%)		(0.20%)
MEDTECH(3) | Surgery | U.S.
Sales by segment of business
Sales to customers	$ 992	1,035	$ 1,913	1,933
Percent Change (as a percent)	(4.10%)		(1.00%)
MEDTECH(3) | Surgery | International
Sales by segment of business
Sales to customers	$ 1,458	1,487	$ 2,971	2,961
Percent Change (as a percent)	(2.00%)		0.30%
MEDTECH(3) | Surgery | ADVANCED
Sales by segment of business
Sales to customers	$ 1,156	1,168	$ 2,302	2,286
Percent Change (as a percent)	(1.00%)		0.70%
MEDTECH(3) | Surgery | ADVANCED | U.S.
Sales by segment of business
Sales to customers	$ 454	459	$ 871	864
Percent Change (as a percent)	(1.10%)		0.80%
MEDTECH(3) | Surgery | ADVANCED | International
Sales by segment of business
Sales to customers	$ 702	708	$ 1,431	1,421
Percent Change (as a percent)	(0.90%)		0.70%
MEDTECH(3) | Surgery | GENERAL
Sales by segment of business
Sales to customers	$ 1,294	1,354	$ 2,582	2,608
Percent Change (as a percent)	(4.50%)		(1.00%)
MEDTECH(3) | Surgery | GENERAL | U.S.
Sales by segment of business
Sales to customers	$ 538	576	$ 1,042	1,069
Percent Change (as a percent)	(6.40%)		(2.50%)
MEDTECH(3) | Surgery | GENERAL | International
Sales by segment of business
Sales to customers	$ 756	779	$ 1,540	1,540
Percent Change (as a percent)	(3.00%)		0%
MEDTECH(3) | Vision
Sales by segment of business
Sales to customers	$ 1,241	1,183	$ 2,498	2,328
Percent Change (as a percent)	4.90%		7.30%
MEDTECH(3) | Vision | U.S.
Sales by segment of business
Sales to customers	$ 496	467	$ 1,017	939
Percent Change (as a percent)	6.20%		8.30%
MEDTECH(3) | Vision | International
Sales by segment of business
Sales to customers	$ 745	716	$ 1,481	1,389
Percent Change (as a percent)	4%		6.60%
MEDTECH(3) | Vision | CONTACT LENSES / OTHER
Sales by segment of business
Sales to customers	$ 894	868	$ 1,804	1,725
Percent Change (as a percent)	2.90%		4.50%
MEDTECH(3) | Vision | CONTACT LENSES / OTHER | U.S.
Sales by segment of business
Sales to customers	$ 374	352	$ 774	723
Percent Change (as a percent)	6.60%		7.20%
MEDTECH(3) | Vision | CONTACT LENSES / OTHER | International
Sales by segment of business
Sales to customers	$ 519	517	$ 1,030	1,003
Percent Change (as a percent)	0.40%		2.70%
MEDTECH(3) | Vision | SURGICAL
Sales by segment of business
Sales to customers	$ 347	314	$ 694	602
Percent Change (as a percent)	10.50%		15.20%
MEDTECH(3) | Vision | SURGICAL | U.S.
Sales by segment of business
Sales to customers	$ 122	115	$ 243	216
Percent Change (as a percent)	5.10%		12.10%
MEDTECH(3) | Vision | SURGICAL | International
Sales by segment of business
Sales to customers	$ 225	199	$ 451	386
Percent Change (as a percent)	13.60%		17%
CONSUMER HEALTH and PHARMACEUTICAL [Member] | OTC [Member] | CHINA
Sales by segment of business
Sales to customers		$ 100		$ 200

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Segment Reporting Information [Line Items]
Worldwide income before tax	$ 5,840	$ 6,662	$ 11,702	$ 14,091
Percentage Change in Operating Income Loss	(12.30%)		(17.00%)
Amount prepaid and due to manufacturers			$ 900
Restructuring charges	$ 85	56	155	109
PHARMACEUTICAL(1) | bermekimab
Segment Reporting Information [Line Items]
In-process research and development expense			600
MedTech
Segment Reporting Information [Line Items]
Amortization			500	500
Restructuring charges			200	100
Operating Segments
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 6,345	6,906	$ 12,432	14,546
Percentage Change in Operating Income Loss	(8.10%)		(14.50%)
Operating Segments | CONSUMER HEALTH (1)
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 784	866	$ 1,470	1,708
Business Exit Costs	$ 268	0	$ 370	0
Percentage Change in Operating Income Loss	(9.50%)		(13.90%)
Amortization	$ 100		$ 200	200
Litigation expense	100	100	100	100
Operating Segments | PHARMACEUTICAL(1)
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 4,420	4,294	$ 8,344	9,463
Percentage Change in Operating Income Loss	2.90%		(11.80%)
Amortization	$ 700	800	$ 1,500	1,700
Gain (loss) on disposition of assets			600
Unrealized gain (loss) on securities	(100)	200	(500)	100
Supply network costs	200		200
Operating Segments | MedTech
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 1,141	1,746	$ 2,618	3,375
Percentage Change in Operating Income Loss	(34.70%)		(22.40%)
Amortization	$ 300	300
Litigation expense	300		$ 300
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 237	$ 244	$ 360	$ 455

Segments of Business and Geog_5

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Sales by geographic area
Sales	$ 24,020	$ 23,312	$ 47,446	$ 45,633
Percentage Change In Sales By Geographic Area	3%		4%
United States
Sales by geographic area
Sales	$ 12,197	11,919	$ 23,611	23,030
Percentage Change In Sales By Geographic Area	2.30%		2.50%
Europe
Sales by geographic area
Sales	$ 6,085	5,668	$ 12,109	11,082
Percentage Change In Sales By Geographic Area	7.30%		9.30%
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,536	1,367	$ 3,018	2,791
Percentage Change In Sales By Geographic Area	12.40%		8.10%
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 4,202	$ 4,358	$ 8,708	$ 8,730
Percentage Change In Sales By Geographic Area	(3.60%)		(0.20%)

Acquisitions and Divestitures -

Acquisitions and Divestitures - Narrative (Details) - Evra and Doxil $ in Billions	3 Months Ended
	Apr. 04, 2021 USD ($) brand
Business Acquisition [Line Items]
Number Of Brands | brand	2
Gain (loss) on disposition of assets | $	$ 0.6

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions

1 Months Ended

3 Months Ended

Apr. 30, 2022 USD ($)

Mar. 22, 2022 USD ($)

Oct. 31, 2021 USD ($)

Jun. 30, 2021 USD ($)

Jun. 30, 2020 USD ($)

Jan. 31, 2020 USD ($)

Oct. 31, 2019 USD ($)

Jul. 31, 2018 USD ($)

Mar. 29, 2020 USD ($)

Jul. 03, 2022 claim claimant patient cases

Sep. 30, 2021 cases

May 31, 2021 cases claimant

Oct. 31, 2020 USD ($)

Apr. 30, 2015 claim

Legal Proceeding (Textuals)

Number of pending claims | claim

60

Rasmussen Instruments, LLC

Legal Proceeding (Textuals)

Damages awarded | $

$ 20

ASR

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

190

Pinnacle Acetabular Cup System

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

1,900

Pelvic Meshes

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

9,500

Risperdal

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

2,100

XARELTO

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

3,000

Talc

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

40,300

Invokana

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

10

Physiomesh

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

4,700

Opioid

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

3,500

Contact Lenses

Legal Proceeding (Textuals)

Number of pending claims | claim

30

Elmiron

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

1,300

Judicial Ruling

Legal Proceeding (Textuals)

Damages awarded | $

$ 6.8

$ 8,000

Pending Litigation

Legal Proceeding (Textuals)

Number of pending claims | claim

1,000

Loss contingency, estimate of possible loss | $

$ 4,000

$ 5,000

Loss contingency, estimate of additional possible loss | $

$ 1,000

Pending Litigation | Physiomesh

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

4,300

Number of claims within settlement agreement | cases

3,729

Number of pending claims | cases

126

3,600

DePuy ASR U.S. | Settled Litigation

Legal Proceeding (Textuals)

Number of patients in settlement | patient

10,000

Baby Powder | Talc

Legal Proceeding (Textuals)

Reserve established | $

$ 2,000

Baby Powder | Judicial Ruling | Damages from Product Defects

Legal Proceeding (Textuals)

Litigation contingency | $

$ 2,100

$ 4,700

Payments for legal settlements | $

$ 2,500

Oklahoma Attorney General vs. Johnson & Johnson and JPI | Settled Litigation

Legal Proceeding (Textuals)

Damages awarded | $

$ 465

Surgical Mesh Products Marketing | Judicial Ruling

Legal Proceeding (Textuals)

Damages awarded | $

$ 302

$ 344

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 85	$ 56	$ 155	$ 109
Supply Chain
Restructuring Cost and Reserve [Line Items]
Restructuring charges	128		200
Restructuring charges recorded to date	2,000		2,000
Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Cost savings expected	800		800
Restructuring estimated cost	2,300		2,300
Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Cost savings expected	600		600
Restructuring estimated cost	2,100		2,100
Supply Chain | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Restructuring charges	85		155
Supply Chain | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	17		33
Supply Chain | Other (income) expense
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 26		12
MedTech
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 200	$ 100

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 85	$ 56	$ 155	$ 109
MedTech
Restructuring Reserve [Roll Forward]
Reserve balance beginning			137
Restructuring charges			200
Cash settlements			(202)
Settled non cash			(24)
Reserve balance ending	111		111
MedTech | Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning			112
Restructuring charges			0
Cash settlements			(23)
Settled non cash			0
Reserve balance ending	89		89
MedTech | Asset Write-offs/Sales
Restructuring Reserve [Roll Forward]
Reserve balance beginning			0
Restructuring charges			(11)
Cash settlements			35
Settled non cash			(24)
Reserve balance ending	0		0
MedTech | Other
Restructuring Reserve [Roll Forward]
Reserve balance beginning			25
Restructuring charges			211
Cash settlements			(214)
Settled non cash			0
Reserve balance ending	$ 22		$ 22